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ABSTRACT 
ALJASSIM, KHOLOUD AHMED., Master of Sciences: June: 2018, Biomedical 
Sciences. 
Title: Profiling of Chronic Myeloid Neoplasms through RNA Sequencing Analysis. 
Supervisor of Thesis: Dr. Pejman Hanifi Moghaddam.  
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative 
disorder resulting from the neoplastic transformation of hematopoietic stem cells. A 
higher number of (54%) CML patients in Qatar failed to respond to the treatment 
compared to those of (34%) internationally. Classification of the different stages of 
the disease is done in the clinic but is not sufficient; there is a great need to find 
markers that can be used to stratify the stages of the CML disease and furthermore 
monitor those that are undergoing treatment. 
Aims and Objectives: For this study, we aimed to identify the disease-specific 
profile of genes (transcripts) by analyzing the RNA sequencing of patients, recruited 
from two different stages of CML disease i.e. Chronic Phase (CP) and Complete 
Remission (CR). Our objective was to see if we can identify a disease-specific group 
of transcripts. 
Methods: A total of 16 subjects were recruited for the study, which included nine 
patients with chronic phase (CP), three with complete remission and four healthy 
individuals (Controls, (CNT). RNA extracted from frozen PBMCs or fresh blood was 
used for RNA sequencing and analysis using Hiseq Illumina 4000. 
Results and Discussions: We identified a subset of 23 transcripts and classified them 
into four different groups. We discovered that eight transcripts: MAZ_4, RIT1_3, 
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BUB1_4, CFLAR_5, PARVG_6, SENP5_6, GATS_1, TAOK3_4 were significantly 
and differentially expressed in the chronic phase patients only compared to five 
transcripts that segregated the complete remission from the rest of the cohort study 
and These are HNRNPA3_4, SLC4A7_3, TBC1D4_8, CTC1_1, GRAMD1A_6. The 
following five transcripts: U2SURP_5SEPT9_2, DPY19L3_8, CYTH4_1, PLXNB2_8 
were differentially expressed in both groups of patients compared to control group. 
These that are shared between CP and CR group might indicate that study subjects in 
the complete remission did not fully recover and might need closer monitoring and to 
validate this current observation will be through a longitudinal follow up for some 
patients in complete remission using other diagnostic methods to examine the ratio of 
BCR-ABL1 fusion gene and the expression level of these shared transcripts between 
CP and CR groups. 
Conclusion: This study provides sets of the promising genes (transcripts) that have 
the potential to be used to stratify CML patients into complete remission and chronic 
phase groups. These findings have the potential for following-up and to specifically 
determine the treatment dose. Furthermore, some of these differentially expressed 
genes (transcripts) might be a potential therapeutic target or could be used as 
prognostic biomarkers. 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
According to the World Health Organization (WHO), Myeloproliferative Disorders 
(MPDs) can be classified into different groups including: chronic myeloid leukemia 
(CML), chronic neutrophilic leukemia, polycythemia vera (PV), primary 
myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia, 
mastocytosis and unclassifiable MPDs. Among these hematopoietic neoplasms, CML 
is the only clonal myeloproliferative disease resulting by a reciprocal translocation 
between portions of chromosome 22 and chromosome 9 of the BCR and ABL genes 
respectively (Koptyra et al., 2006) This alteration creates BCR- ABL1 fusion 
oncogene with shortened chromosome 22 known as Philadelphia chromosome, the 
unique genetic abnormality of CML (Green, 2010) that is necessary for the 
manifestation of chronic myeloid leukemia (Herrmann et al., 2014).  
The resulted in BCR- ABL1 fusion transcripts are different in sizes and this based on 
the breakpoint regions in both BCR and ABL1 genes. In BCR genes the major 
breakpoint cluster regions involving exons (e12- e16) which commonly referred to as 
(b1-b5), while the breakpoints in ABL gene usually takes place between exons a1 and 
a2 as a result of alternative splicing. It is found that the fusion transcripts generated 
with e13a2 (b2a2) and e14a2 (b3a2) junctions are frequently encode for 210 kDa 
protein known as p210
BCR/ABL
, in which strongly
 
correlated with an active tyrosine 
kinase observed in initially diagnosed patients with chronic phase of CML as this 
related to the disease exacerbation (Jain et al., 2016)The size of the resulting BCR-
ABL1 transcript encoding 210 kDa protein is larger than the individual ABL1 (145 
kDa) and BCR (160 kDa) proteins (Deininger, Goldman, & Melo, 2000) in which the 
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tyrosine kinase is constitutively active in the resulted BCR-ABL1 fusion protein sized 
210 kDa. 
Normally, Tyrosine kinases are an important family of enzymes which act as a key 
mediator in different cellular signaling transduction pathways through 
phosphorylation of tyrosine residues of the target receptor in response to external and 
internal stimuli leading to cell growth, differentiation, metabolism, and apoptosis. 
These roles of Tyrosine kinases are essential for normal cell messages and 
preservation of cellular homeostasis. However, Tyrosine kinases have been implicated 
in cancer and acquired mutation which makes these enzymes constitutively active and 
phosphorylate the downstream cascade and developing neoplastic hallmarks in 
cancerous cells (Paul & Mukhopadhyay, 2004) It has been shown that the p210
BCR/ABL
 
protein is involved in the pathogenesis of human CML by introducing p210
BCR/ABL
 
retrovirus protein into the mice bone marrow stem cells, which resulted in subsequent 
development of a myeloproliferative disease with the CML pathological and clinical 
features (Di Bacco, Keeshan, McKenna, & Cotter, 2000) Another investigation 
confirmed the key role of p210
BCR/ABL 
production
 
in CML pathogenesis through 
identification of particular coding sequence in CML-mRNA when researchers using 
K562, a human leukemic cell line which representing an earlier stage of granulocyte 
maturation in their study, thus enable the investigator to measure the p210
BCR/ABL
 
activity in vitro in different cellular contexts
 
(Di Bacco et al., 2000) 
Myeloproliferative disorders (Tefferi & Vardiman), recently known as 
Myeloproliferative Neoplasms (Klco, Vij, Kreisel, Hassan, & Frater) are 
heterogeneous group of hematopoietic disease which characterized by excessive 
clonal production of one or more hematopoietic cell lineages in the bone marrow 
which might be progressed to acute conditions.  
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In normal hematopoetic cells, the proliferation, differentiation and survival of these 
cells are controlled by hematopoietic growth factors including; interleukin 3 (IL-3), 
stem cell factor, erythropoietin, interleukin 6 (IL-6), thrombopoietin, and colony 
stimulating factor 2 (CSF-2), which are responsible for activating signaling pathways 
when adhering to cell surface receptors and resulting in phosphorylation of 
downstream cascade. However, BCR-ABL1 oncogene displaying aberrant role in 
cancerous cells by achieving the growth factor autonomy, which in turn impact the 
capacity of leukemic cells to adhere and invade over continuous stimulating signaling 
pathways, hence the potential function of this oncogene is the activation of cytokine 
signal transduction pathway through cytokine recruitment which in turn recruiting 
kinases proteins in signal transduction pathway to eventually reaching the 
transcription factors which affect different cellular processes. Moreover, BCR-ABL1 
tyrosine kinase causes abnormal expressions of cell cycle control genes through the 
inhibition of the normal role of c-ABL gene including the regulation of the gene 
transcription, integrin signaling, and cell cycle. The high activity of BCR-ABL1 
tyrosine kinase which demonstrated mainly in the cytoplasm will accelerate the 
activity of the machinery genes of the cell cycle including Cyclins D2- and D3-
associated Cyclin-Dependent Kinase 4 (CdK4) and Cyclin-Dependent Kinase 6 
(Cdk6) which allows the progression of the cell cycle phases from G1 to S. This will 
phosphorylate Rb1 suppressor gene followed by an increase in transcription factors 
which irreversibly inhibit the activation of Rb1 gene and allows the cell cycle 
progression to S phase. On the other hand, BCR-ABL1 fusion gene can cause the 
delay in the cell cycle transition from G2 to mitotic checkpoint (M) which necessary 
for the DNA repair lead to a failure in apoptosis (Di Bacco et al., 2000). 
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Currently, many clinical and laboratory findings propose that the abundant existence 
of Philadelphia chromosome (Ph) in patients sample is strictly correlated with poor 
prognosis and treatment failure since the BCR-ABL1 oncogene with it is malignant 
behavior is capable to induce genomic instability leading to multiple mutations which 
observed in different phases of CML disease as these genetic alterations encoded by 
BCR-ABL1 genes making cells resistant to therapies that target mutated tyrosine 
kinase domain. These drugs are known as Tyrosine Kinase Inhibitors (TKIs) in which 
Imatinib Mesylate (IM), the first drug was discovered for this purpose. It is observed 
that only 4% of newly diagnosed CML-chronic phase patients per year have a 
therapeutic resistance. The reason for the treatment failure has been reported to be 
BCR-ABL1 kinase domain that generates reactive oxygen species (ROS) from 
mitochondrial respiratory chain (MRC) (Flis, Irvine, Copland, Bhatia, & Skorski, 
2012) since BCR-ABL1 oncogenic tyrosine kinase has two major roles in leukemia, 
the first one is the constitutive activation of the downstream signaling pathways with 
stimulation of the growth factor independence. The second role of BCR-ABL1 fusion 
gene is the induction of genomic instability such as chromosomal translocation and 
mutations which resulted in DNA repair failure leading to DNA damage. In leukemic 
cells, the increased in oncogene activity with genomic abnormality correlated with the 
generation of reactive oxygen species (ROS) which considered as an inevitable 
byproduct of oxidative reduction process in mitochondria. These oxidative molecules 
combined with the dysregulated pathway of DNA repair causing an accumulation of 
oxidative DNA damage which in turn cause a resistance to IM  (Koptyra et al., 2006).  
The function of p145
ABL
 protein, which is the tyrosine kinase (TK) and the product of 
Abelson gene is controlling of the cell growth, induction of apoptosis and DNA 
repair. Although P145
ABL
 protein located in the nucleus, some studies revealed its role 
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in cell signaling for integrin and other cells receptors such as B-cell receptor (eg. 
CD19). Tyrosine kinase domain in the c-ABL gene is regulated by SH3 and SH2 
regions, in which SH3 is a negative regulator of c-ABL activity. Any mutation 
acquired to SH3 region will constitutively activate the kinase domain, whereas SH2 is 
the positive regulator (Di Bacco et al., 2000; Shet, Jahagirdar, & Verfaillie, 2002).  
CML is not like other cancers. CML is a disease of the bone marrow in which disease 
phases are assigned based on specific factors such as the patient’s age, immature 
white blood cells count, and the spleen enlargement. CML can be divided into four 
clinical distinct phases, an initial chronic phase (CP) which characterized by the 
presence of Philadelphia-chromosome (Ph+) with BCR and c-ABL fusion gene in 
which cells are responsive to growth factors and reduced apoptosis, show altered 
adhesion and activation of different hematopoietic signaling pathways and the disease 
can be easily controlled in this phase. This phase usually associated with a median 
survival of 4 to 5 years. However, some patients have treatment failure that can 
undergo to accelerated phase (AP) which last for 4 to 6 months with difficulty in 
controlling the blood count by myelosuppressive treatment. CML-AP almost 
constantly progress to Blast Crisis (BC) phase if not treated and can be differentiated 
from other phases by other molecular changes such as the presence of an extra copy 
of Ph-chromosome (BCR-ABL1) and high rate of P53 and Rb1 gene mutation in 
which these genes are almost implicated in the transformation. Alterations in P53 and 
Rb1 genes usually occur in 20% to 30% of blast crises cases but their structure 
remained normal in chronic phase (Di Bacco et al., 2000). 
Chronic Myeloid leukemia can be implicated at any age group, however, it accounts 
for 15 % of adult leukemia with the median age of onset being 67 years‖ (O'Brien et 
al., 2012). 
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Treatment failure with Imatinib Mesylate (IM) reached a high percentage of 54% of 
CML patients in Qatar where the resistance rate is high compared to that reported by 
International Randomized Study of Interferon and STI571 (IM) (IRIS) which reaches 
to 35% A study conducted in Qatar in 2014 concluded that 14% of the treatment 
failure caused by point mutation with unique tri-nucleotide insertions and the most 
common cause of IM failure was documented in 50% of cases due to additional 
chromosomal abnormalities (ACAs) , 28% of cases showed drug resistance for 
unknown reasons and 14% of patients stopped IM due to intolerance (Al-Dewik, 
Jewell, Yassin, El-Ayoubi, & Morsi, 2014). 
Currently, most of CML patients are effectively treated using both the first and second 
generation tyrosine kinase inhibitors (TKIs) including IM, Nilotinib, and Dasantinib 
respectively as therapeutic agents in which IM induces high rate of molecular 
response and improved overall survival rate and has well-documented safety profile 
while Nilotinib and Dasantinib cause rapid molecular response and characterized with 
a reduced risk of the disease transformation to blast crisis  Although, all three drugs 
are used as the first line therapeutic option and they are well-correlated with the time-
dependent milestone molecular response of BCR-ABL1 gene after 3, 6 and 12 
months, challenges still remain when using these drugs to treat the disease in some 
patients such as several genetic and epigenetic expression mysteries of CML, no 
accurate algorithm as no specific biomarkers can be used to identify the risk of the 
disease progression at diagnosis. In addition to that, the clinical scoring system used 
at the time of CML diagnoses such as Sokal, Hasford and European Long-Term 
survival (ELTS) risk scores which can provide a significant prognostic information 
useful to determine the disease risk, these scoring systems themselves are with limited 
specificity and sensitivity. Therefore, by investigating novel biomarkers will improve 
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the prediction of disease progression and enable the selection of the first- line 
treatment and enhance the optimal responses to TKI therapy (Marum et al., 2017). 
Based on the knowledge of central dogma concept by a molecular biologist that the 
genetic information located only in protein-coding regions of the genome and they 
believed that any transcript originates from non-coding regions have been considered 
as a transcriptional noise.  
This view persists for a long time period until many evidence and research change 
their old perspective. It is well-known that cancer is a multistep genetic disease which 
can be caused by the mutation in protein coding region but several studies indicate 
that mutations also can be found in non-protein coding regions as the protein-coding 
gene account for 2% which means that more than 98% of the human genome are non-
protein coding. These regions are transcribed into non-coding RNA which can be 
classified based on the transcript length into small non-coding RNA and long non-
coding RNA (lncRNA) (X. Chen, Yan, Zhang, & You, 2017). 
Increasing evidence is indicating that lncRNAs are considered as regulators of almost 
every cellular process, and expression of these non-coding molecules appears to be 
firmly regulated in physiological conditions while deregulated expression of these 
molecules drives toward several human diseases phenotypes including cancer 
(Beermann, Piccoli, Viereck, & Thum, 2016).  
A list of lncRNAs discovered by some studies showed that many of which are 
abundantly expressed in differentiated tissues of specific cancer and they are related 
to specific cell type more than the mRNA. In the context of the gene sequence, It is 
known that many functional protein defects resulted by genetic mutations but 
lncRNAs biology has remained impervious for understanding how sequence affects 
function in these molecules. Recently, many studies revealed that the molecular 
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mechanisms of lncRNAs serve to understand the role of these molecules as signals of 
specific cellular status, prognostic biomarkers and could be exploited as therapeutic 
targets of cancer. Therefore, emerged technology such as Next Generation 
Sequencing (NGS) enables the researchers to expand their investigation to identify 
cancer-associated lncRNAs (Schmitt & Chang, 2016). 
During the last decades, multiple studies identified the relevance of non-coding RNAs 
in gene regulation. However, dysregulation of these molecules was increasingly 
linked to diverse human diseases and among these dysregulated transcripts of lncRNA 
is H19, but the profiling of protein-coding genes (mRNAs) and non-protein coding 
genes particularly, lncRNAs expression in CML patients using high throughput 
method such as NGS will be the first study of its kind in Qatar which assists the CML 
patients to overcome the disease complications and treatment failure.  
1.2 Aim of the study  
The aim of this study is to explore and identify the profile of transcripts expression in 
different phases of Chronic Myeloid Leukemia (CML) using RNA-sequencing 
technology which considered as a highly dynamic method with the capability of 
detecting novel genes (transcripts) from different aspects. 
1.3 Research question  
Can we use a transcript profile as a tool to stratify the different clinical stages of 
Chronic Myeloid Leukemia (CML) disease including chronic phase (CP) and 
complete remission (CR) in Qatar. 
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CHAPTER 2: LITERATURE REVIEW 
2.1. Chronic Myeloid Neoplasm 
2.1.1. Definition and Molecular Mechanism of Chronic Myelogenous Leukemia  
CML is the most common clonal MPNs, which was first described by Virchow and 
Benett in 1845 as a case of hypertrophy of the spleen and liver, in which death took 
place from suppuration of the blood. (Klco et al., 2010) In its initial phase, CML is 
characterized by unclear symptoms such as abdominal discomfort and weight loss, 
among others. CML can be identified by an expansion of the cells of the granulocytic 
lineage. Initially referred to as MPNs, chronic MPDs refer to a class of myeloid 
hematological malignancies, which occur mainly among the adults (Klco et al., 2010) 
The disorders have a common characteristic whereby one or more of hematopoietic 
cell lineages highly extended in the bone marrow. The naming and categorization 
have been revised by the World Health Organization to emphasize on the stem-cell 
derived heritage of the disorders.  
The chronic phase of CML is characterized by a larger percentage of mature cells, as 
well as myeloid progenitor cells in the extramedullary tissues and in the blood 
followed by a maturation arrest in lymphoid or myeloid lineage whereby it transforms 
within a period of 3-4 years (Shet et al., 2002). The malignancy is also associated with 
Philadelphia chromosome which is a genetic abnormality resulting from BCR and 
Abelson (ABL) genes rearrangement. 
 A study demonstrated that more than 90% of the CML patients have Philadelphia 
chromosomes. The BCR-ABL1 fusion gene is usually translated into an oncoprotein, 
P210
BCR/ABL 
which facilitates the malignant transformation of the cells (Shet et al., 
2002). However, despite the strides have been undertaken in studying the progression 
 10 
 
of the disorder, the process through which CML changes from its chronic form to the 
blast crisis remained unknown.  
In their study, Deininger, Goldman, and Melo (2000) provide a review of the 
physiologic functions of the translocation partner which results in the development of 
CML. ABL gene is one of the translocation factors; is a human homolog of the v-abl 
oncogenes which encodes tyrosine kinase. Human ABL is a form of protein that has 
two isoforms resulting from splicing of the first exon (Deininger et al., 2000) The 
protein has several domains including SH1 which is responsible for carrying the 
tyrosine kinase function. On the other hand, SH2 and SH3 are essential in allowing 
ABL protein to interact with other proteins. For example, the center of the protein 
molecule which is rich in Proline interacts with the SH3 domains of proteins like Crk 
(Deininger et al., 2000). Therefore, in its usual form, ABL is an essential protein in 
regulating the cell cycle, integrin signaling whereby information is transmitted within 
the cellular environment as well as providing the cellular response to genotoxic stress 
(Deininger et al., 2000) On the other hand, BCR is a 160kDa protein which is similar 
to ABL in terms of expression. The protein has several structural functions. For 
instance, the N-terminal exon is responsible for encoding serine-threonine kinase. 
Also, the N-terminus of the protein has a coiled domain for dimer formation 
(Deininger et al., 2000). The C-terminus has GTPase activity which is essential in 
regulating actin polymerization.  
In order to understand the molecular mechanism of CML, it is important to review the 
biology of Philadelphia chromosome (Ph+) Ph+ refers to a genetic disorder due to a 
short chromosome 22. In addition, there is a translocation of genetic material between 
this chromosome and chromosome 9 (Shet et al., 2002) Thus, c-ABL, proto-
oncogenes are transported from chromosome 9 to M-BCR location on chromosome 
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22. This forms the BCR-ABL fusion gene that encodes P210
BCR/ABL
. The new 
oncoprotein is associated with abnormal activities in the body including an increase in 
the rate of binding to the actin skeleton. Also, P210
BCR/ABL 
has an increased tyrosine 
kinase activity (Shet et al., 2002) Consequently, the abnormal cellular activities 
contribute to the growth of leukemia cells. As the cells proliferate, coupled with the 
transgenic expression of P210
BCR/ ABL
, leukemia, lymphomas and CML syndromes are 
induced. The breakpoints at 9q34 region of ABL gene at chromosome 9 can occur 
anywhere either upstream toward the first exon of 1b or downstream toward the 
second exon of 1a or the breakpoints could occur between the two exons in that 
region. Contrastly, the breakpoints within BCR gene determined by 1 of 3 breakpoint 
cluster regions (BCR). It is demonstrated that in most of the CML patients, the 
breakpoint of the BCR gene occurs within a 5.8kb area surrounding BCR gene exons 
12 to 16, which originally known as exons b1 to b5 while the breakpoint of BCR gene 
at this particular region defined as Major breakpoint cluster (M-bcr) (Deininger et al., 
2000). 
New therapies aimed at arresting CML during the chromosomal translocation phase 
have been developed. The targeted therapy for Ph chromosome in CML through the 
synthesis of IM has been used for quite some time. However, the efficiency of this 
treatment has been put to question because of the persistence and resistance of the 
disease. Consequently, about 50 mutations are known to have developed from Ph-
CML resistance to the drug (Al-Dewik et al., 2014) Thus, it is vital to understand all 
the dynamics of CML including molecular reaction to various interventions to prevent 
the development of further mutations in future.  
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2.1.2. Incidence and Mortality 
The incidence rate of the CML is on the rise. According to the American Cancer 
Society, more than 10% of the current cases of leukemia being diagnosed are chronic 
myeloid leukemia. The age average at the time of CML diagnosis is 64 years old and 
is rare among the children. However, it is slightly more prevalent in male than female 
as demonstrated in figure 1 (Höglund, Sandin, & Simonsson, 2015). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The yearly incidence of CML per 100, 000 people of different age and 
gender groups. 
 
The data also suggests that 1 in every 526 persons in the United States will be 
diagnosed with CML in their lifetime. The American Cancer Society further indicates 
that before the end of 2017, more than 8, 000 cases of CML will be diagnosed in the 
United States with more than 1,000 people dying as a result of CML has a 5-year 
survival rate depending on the phase of the disease among other factors such as the 
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biological characteristics and presentation as well as the patient’s response to 
treatment ("Key Statistics for Chronic Myeloid Leukemia," 2018). 
The advancement in scientific research has contributed towards the development of 
sound treatment options which are likely to increase the survival rate. The most 
available data shows that the rate has doubled from 31% to 66% from the 1990s to 
2012. A study conducted in 2014 shows that CML patients constantly taking IM drug 
and undergoing stem cell transplantation have a high survival rate of 93%. Besides, 
more than 90% of the patients live for more than five years (Sacha, 2014). 
Singh, Henley, and Ryerson (2017) provide an analysis of the cancer incidents and 
mortality for the year 2013. In addition, the study shows the trends for the years 1999 
to 2013 as per the data from the Centers for Disease Control and Prevention (CDC) 
and the National Cancer Institute (NCI). CML is among the cancers with a high 
mortality rate in the United States. Since cancers are reported, all states and health 
organizations, pathology laboratories, and physician offices are required to submit 
data for the reportable cancer diagnosis to the central cancer registry calculation of 
incident and mortality rate (Singh, 2017) Part of the reason why it has not been 
possible to provide accurate and comprehensive incident and mortality rates for most 
of the cancers is due to incompetent cancer reporting in some states (Jemal, Siegel, 
Xu, & Ward, 2010) Leukemia is the most common type of cancer which accounts for 
most of the expected new cancer cases at 43,050 and the estimated number of deaths 
at 21,840 for both gender in 2010 in the United States. The use of IM as the primary 
therapy of CML has reduced both the incident and mortality rate significantly 
("CHRONIC MYELOGENOUS LEUKEMIA," 2014) Consequently, the treatment 
has provided a global health effort which is critical in addressing the burden of non-
communicable diseases. Another reason the increased use and efficiency of IM is its 
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low levels of toxicities giving a major therapeutic benefit in both the adult and 
pediatric population ("CHRONIC MYELOGENOUS LEUKEMIA," 2014). 
Alternative drugs which are essential in reducing the mortality rate of CML include 
Nilotinib and Dasatinib. According to the Union for International Cancer Control 
(2014), CML in the United States has an incidence rate of approximately 1.6/100,000 
In addition, the available data has not shown any association between CML and race 
or ethnicity. Despite the availability of accurate global data on CML, the disorder 
affects approximately 100,000 people worldwide annually ("CHRONIC 
MYELOGENOUS LEUKEMIA," 2014). Currently, the prevalence of CML is much 
higher since treatment with IM prolongs remissions in most of the patients. For 
instance, in 2010, 4870 cases of CML were diagnosed in the United States with 440 
dying of the disease (O'Brien et al., 2012) In 2017, the estimated number of new cases 
is 8,430 and 1,090 deaths ("Key Statistics for Chronic Myeloid Leukemia," 2018). 
Hoglund, Sandin, and Simonsson (2015) explored in their study the epidemiology of 
CML and the underlying risk factors for developing the disease. The study results 
were a complement to Union for International Cancer Control (2014) findings that the 
prevalence of CML is increasing progressively as a result of improvement in therapy 
regimens such as IM among other tyrosine kinase inhibitors. Another reason 
suggested to explain the phenomenon is as a result of the general improvement in life 
expectancy across the population (Höglund et al., 2015) A section of studies and data 
collected over the years indicated that the prevalence of CML in 1998, 2003 and 2007 
was 5.8, 6.8 and 7.3 per 100,000 people respectively (Höglund et al., 2015) As more 
effective therapeutic regimens are developed, the prevalence of CML is expected to 
increase as the survival rate increases. For instance, Hoglund, Sandin, and Simonsson 
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(2015) estimated that the prevalence of CML in the United States will accelerate by 
more than 35 times the current and the future incidence by 2050.  
Although the essential etiology of CML remains unknown, factors such as ionizing 
radiation have been identified as the key link to CML. For many years, smoking has 
been regarded as a risk factor in the development of CML. However, recent case-
control studies have suggested a weak association between the two variables 
(Höglund et al., 2015) The introduction of tyrosine kinase inhibitors has paved the 
way for better understanding of CML especially on progression as well as the survival 
rates. Most studies confirm that availability of treatment regimen has increased the 
survival rates of CML dramatically (Höglund et al., 2015) In a study carried out by 
Kantarjian et al. (2012) to examine the survival rate of CML since the introduction of 
IM. The medical records for 1,569 of CML patients who had been referred to a health 
facility within one month of diagnosis between 1965 and 2011 were examined. Out of 
the 1,569 cases, 1,148 were in the chronic phase, 175 were in the accelerate phase 
while the remaining 246 were in the blast crisis phase (H. Kantarjian et al., 2012). On 
average, the study suggested an improved survival rate to about 71% among patients 
treated with IM since 2001. Among the CML patients in the blast crisis phase, the 
survival rate also improved with the introduction of IM but has remained seven 
months since 2001 (H. Kantarjian et al., 2012) Survival has been more significant 
among the patients in the chronic phase and the accelerated phase.  
2.1.3. Therapeutic Options and Treatment Algorithms 
CML treatment and management has evolved over the last few years from 
hematopoietic stem cell transplantation (HSCT) to the current standard regimen. 
Introduction of tyrosine kinase inhibitors (TKIs), Imatinib Mesylate (IM) has 
revolutionized the treatment for this form of leukemia. However, with its continued 
 16 
 
use, resistances to TKIs occur. IM is on the rise resulting in over 50 different types of 
mutations. As a result, there is a need to develop alternative treatment modalities for 
CML patients. Improvement of scientific research has paved the way for better 
understanding of the molecular biology and progression of CML. Consequently, this 
has enhanced the efforts to develop therapeutic options to manage the condition. The 
current treatment modalities are designed to inhibit the activity of tyrosine kinase in 
BCR-ABL1 (Forrest, Jiang, Eaves, & Smith, 2008). 
TKIs (Imatinib, Dasatinib, Nilotinib) have contributed to a milestone in the 
management of CML. According to Forrest, Jiang, Eaves, and Smith (2008), before 
the development of these drugs, the use of interferon alpha was the standard 
treatment. Interferon was given together with cytarabine. Other regimens used include 
busulfan and hydroxyurea. However, interferon alpha was commonly used because it 
prolongs the survival rate compared to the alternatives. However, this therapeutic tool 
had major disadvantages. For example, it is known to produce dose-related toxicities. 
In addition, the drug’s survival benefit was realized in a small number of patients. 
Unlike TKIs, interferon alpha has major side effects, and patient monitoring is 
required in order to reduce the dose or discontinue the treatment (Forrest et al., 2008) 
Imatinib Mesylate (IM) is the first TKI developed. The drug is useful in treating all 
the phases of CML. The drug was approved after a clinical trial involving 1106 
patients who were newly diagnosed with CML in chronic phase. Follow-up studies on 
the patients after 60 months showed that the drug was significant both in increasing 
survival rate and promoting cytogenetic response at the rates of 93% and 87% 
respectively (Forrest et al., 2008) For newly diagnosed individuals in the chronic 
phase, a starting dose of 400 mg is recommended on a daily basis. On the other hand, 
CML patients with additional disorders including cytogenetic abnormality and the 
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presence of Ph-chromosome require an elevated dose of about 600 mg per day. 
Patients under IM therapy should be monitored regularly in order to guide on 
alternative or complementary procedures.  
A study carried out by Forrest et al., (2008) stated that the only known curative 
procedure for CML is HSCT. The risk of relapse following HSCT is 14% (Rizzieri & 
Moore, 2012) It was a standard treatment for patients who both eligible and had 
matching donors. In addition, the survival rate is 61%. However, the system has been 
improved through the introduction of scoring systems which are essential in 
determining mortality following the transplantation. Since IM is used as the standard 
treatment for almost all patients, HSCT is only reserved for patients who do not show 
significant improvement following IM therapy (Jabbour, Fullmer, Cortés, & 
Kantarjian, 2010). 
Rizzieri and Moore (2012) also mentioned the importance of adhering to the 
developed treatment algorithm especially in decision-making, promoting cost-savings, 
improving resource management and minimizing practice variation. These guidelines 
have been used extensively in guiding CML management. Currently, the European 
Leukemia Net (ELN) and the National Comprehensive Cancer Network (NCCN) are 
in the process of developing guidelines to target the arrest mutations in the disease. 
For instance, IM therapy should be stopped if the patient shows a loss of response to 
the drug, has progressed to the accelerated phase or the blast crisis phase or if the 
patient exhibits an unsatisfactory initial response (Rizzieri & Moore, 2012) Once the 
patient commences on the therapy, peripheral blood counts should be monitored. 
Once they normalize, additional hematological responses should be examined to 
guide on further clinical decisions (H. M. Kantarjian, Larson, Cortés, Deering, & 
Mauro, 2013).  
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IM therapy requires frequent monitoring for resistance. Ideally, a complete 
hematologic response (CHR) occurs after about three months of therapy. In addition, 
cytogenetic or FISH analysis is done on bone marrow samples. According to Forrest, 
Jiang, Eaves, and Smith (2008), drug monitoring in the course of the treatment should 
be based on Real-Time PCR (RT-PCR) as opposed to the use of cytogenetic analysis 
which has low sensitivity despite being labor intensive. The cytogenetic analysis also 
requires a serial bone marrow aspirate which is both painful and tedious to collect. 
RT-PCR, on the other hand, is more comfortable to conduct because it used peripheral 
blood and is also more sensitive and by using RT-PCR it is possible to identify a 
single abnormal Ph+ cell in a group of 10,000 normal cells. Besides, the method 
allows for detection of the minimal residual disease (Forrest et al., 2008). 
2.2. Coding and Non-Coding RNA 
Many studies showed that RNA molecules can be classified based on their derivative 
regions into protein-coding and non-protein coding transcripts. It is known that the 
majority of well-identified transcripts belong to protein-coding regions of the genome 
and accounts for 2.3% such as mRNAs. However, few of well-characterized non-
protein coding (ncRNAs) transcripts represent the majority of the transcription and 
annotated as ―dark matter‖ once discovered in the last century. These transcripts 
including ribosomal (rRNAs), transfer (tRNAs), small nuclear RNA (snRNAs), small 
nucleolar RNA (snoRNAs) and spliceosomal RNAs (Dinger, Pang, Mercer, & 
Mattick, 2008) Other categories of ncRNAs classified based on their size into Micro 
RNA (miRNAs) and long non-coding RNA (lncRNAs). These classes of ncRNAs 
have a regulatory role and the dysregulated functions of any of these ncRNAs found 
to be implicated in many diseases especially in cancers. These dysregulated 
transcripts could be either oncogenes or tumor suppressor genes. mRNA of the CML 
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has been reviewed extensively in different studies while the identification of ncRNA 
transcripts in CML have been revealed by limited studies using RNA-sequencing 
technology particularly in the state of Qatar.  
2.2.1. Genes Involved in CML Pathogenesis and Clinical Identification 
Progression of the CML is an essential part of the disease pathogenesis.  The BCR-
ABL1 fusion gene is critical to the pathogenesis of CML. In addition, the gene 
continues to undergo expression for the cell to proliferate especially in the acute 
phase. Although the process of evolution to blast crisis is not yet clearly understood, 
studies have shown that CML cells tend to develop additional molecular defects 
before the blast crisis phase (Shet et al., 2002) the first cellular event in the 
progression of CML is decreased apoptosis whereby cells degenerate on their own 
after sometimes for regeneration of new ones. It is a protective mechanism especially 
against cancerous cells or cells that acquiring chromosomal rearrangement, deletion, 
and mutation are critical for continued proliferation of the malignant cells. There are 
multiple mechanisms which contribute towards reduced apoptosis. One of the ways 
BCR-ABL1 exerts the antiapoptotic effect is through the phosphorylation and 
activation of the PI(3)K/Akt pathway (Shet et al., 2002) Another way in which 
apoptosis is slowed down is through PI(3) kinase activation. BCR-ABL1 fusion gene 
also increased expression of BCL-2 which contributes to the antiapoptotic effect. 
Additionally, factors which play antiapoptotic roles such as transcription factor NF- 
κB are activated in CML. Activation of NF- κB has been demonstrated in transgenic 
models. Other pathways that inhibit apoptosis include the RAS pathway which 
elevates the production of cytokines. The level of apoptosis regulation differs 
depending on the phase of CML. In the chronic phase of CML, there is minimal 
protection against apoptosis. However, there is evidence of some level of BCR-ABL1 
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mediated resistance to apoptosis. Lastly, the high rate of BCR-ABL1 mRNA 
expression is the key to the process of pathogenesis.  
Another cellular event in CML progression is blocking the cellular differentiation 
phase (Shet et al., 2002) during hematopoietic differentiation, the pluripotent stem 
cells change both morphologically and functionally to distinct blood cells. 
P210
BCR/ABL 
does not play a direct role in the terminal cell differentiation. However, 
additional factors with elevated cytokine levels, the formation of new oncogenes and 
the inactivation of the tumor suppressor genes block the normal cell differentiation 
(Shet et al., 2002) This phase of disease progression has been useful in the 
development of treatment regimen against CML. Studies showed that by inducing 
differentiation with cytokines, normal hematopoiesis is regulated.  
During the chronic and the progressive phase of CML, both Major Histocompatibility 
Complex (MHC) -restricted and (MHC)-unrestricted are critical especially in 
providing natural control of the (Ph) clone. These mechanisms restrict the regular 
protective role of the T lymphocytes in eliminating the malignant CML cells. Through 
the expression of functional Fas-Ligand, CML progenitor cells take the role of cell 
defense by creating an immune surveillance escape factor. In blast crisis CML, the 
normal functions of Natural killer (NK) cells and activated killer (AC) cells decline 
significantly, and this is thought a factor contributing to disease progression (Siegel, 
Naishadham, & Jemal, 2013).  
 Another factor which facilitates progression of CML to the blast crisis is the ability 
of the BCR-ABL1 mRNA to activate several oncogenic pathways. The presence of 
the gene is also significant in amplifying the activity of BCR-ABL1.  
The amplification of BCR-ABL1 gene in vitro increases resistance to IM. The studies 
confirm the phenomenon that patients in the blast crisis fail to respond to IM. In the 
 21 
 
blast crisis, there is additional translocation which is also in high frequency. As a 
result, Chimeric AML/EVI-1 fusion protein is formed. This protein plays a key role in 
preventing both cell growth and differentiation. Another significant finding in patient 
in the final phase of the disease is the homozygous deletion of p16
INK4a 
in more than 
50% of the cases, in which p16
INK4a
 is a tumor suppressor gene, located on 
chromosome 9 which is a key in the progression of CML from the chronic phase to 
the blast crisis. This gene inhibits cyclin D whose complexes have a role in preventing 
the arrest of the cell cycle (Shet et al., 2002).  
Lastly, CML can progress from the chronic phase to the blast crisis phase due to 
impairment of the DNA repair mechanism (Forrest et al., 2008) The primary cause of 
the non-random chromosomal abnormalities is dysfunctional DNA repair. However, 
this mechanism is not yet well-understood and how it contributes to disease 
progression. but, Shet et al. (2002) approach the issue based on the core role of BCR-
ABL1 and c-ABL. The study suggested that the presence of BCR-ABL1 down-
regulates the role of c-ABL in the repair of damaged DNA. The assertion has been 
proven in a series of in vitro tests on human p210
BCR/ABL
 whereby introduction of 
BCR-ABL fusion gene indicates a reduced rate of repair on DNA protein DNA-PKcs 
(Shet et al., 2002) Therefore, in the progressive phase of CML, the level of BCR-ABL 
protein increases in order to inhibit the rate of DNA repair. Consequently, multiple 
gene defects accumulate leading to disease progression.  
 In CML progression, the disease does not progress to Acute Myelogenous Leukemia 
despite there being a few cases of CML patients developing AML. In addition, the 
progressive phase of CML is different from acute leukemia. The three main phases in 
CML include the chronic phase, accelerated phase, and the blast crisis phase 
("DISEASE PROGRESSION," 2010) Diagnosis of CML is mainly done during the 
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chronic phase of the disease. If the condition goes untreated during the chronic phase, 
the disease progresses to the accelerated and blast crisis phases. The clinical 
symptoms reported for most patients during the chronic period include fever, bone 
pain, recurring infections, and anemia. According to the National CML Society 
(2017), each phase of CML progression can be described based on the number of 
immature cells in the bone marrow. For example, during the chronic stage of the 
disease, the bone marrow has less number of blasts (< 10%) On the other hand, the 
accelerated phase of CML has between 10% - 30% of the blast cells in the bone 
marrow ("DISEASE PROGRESSION," 2010) Lastly, in the blast crisis phase, more 
than 30% of the blood cells in the bone marrow are immature cells.  
Forrest et al., (2008) stated that the first investigation should be done on patients 
presenting the clinical symptoms of CML is white blood cell differential count. In 
addition, a complete blood count (CBC) should be performed immediately after the 
patients’ admission to the hospital. Other tests which are done immediately include 
bone marrow aspiration and biopsy, serum electrolyte, creatinine, uric acid and liver 
function tests (Forrest et al., 2008) Examination of the bone marrow is particularly 
critical in patients presenting the symptoms of leukemia because it provides key 
information in terms of cellular morphology, marrow cellularity, the presence of 
fibrosis, and the current number of blast cells (Forrest et al., 2008) Other tests that 
may be necessary include the detection for the presence or the absence of a deletion in 
chromosome 9 through fluorescent in situ hybridization (FISH) In rare cases, whereby 
the CML patients are negative for Ph, polymerase chain reaction (PCR) is used to 
confirm the disorder. It is also used to detect the presence of Ph chromosome. Forrest 
et al. (2008) pointed out that the importance of PCR not only in the initial diagnosis 
but also in quantifying BCR-ABL1 transcripts. The strategy is important in the course 
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of the treatment because it provides a baseline on which patient care is provided. 
Furthermore, the sensitivity of the test enables the patient to achieve a complete 
cytogenetic response (CCgR). 
Differential diagnosis of CML is required for certainty before the patient is put on 
therapy. When patients are tested and found positive of a high number of blast cells in 
the bone marrow, it is not possible to directly determine the type of leukemia present. 
Differential diagnosis requires additional tests from the bone marrow material or 
blood samples to identify BCR-ABL1 translocation or the Philadelphia Chromosome 
through standard Karyotyping. However, only a few cases of acute lymphoblastic 
leukemic patients have positively diagnosed for Philadelphia chromosome. In most 
cases, only a slight variation is observed in the breakpoint region which suggests the 
presence of Philadelphia chromosome ("DISEASE PROGRESSION," 2010) Another 
diagnostic method in the identification of CML is the examination of the remaining 
normal cells in either the bone marrow or the blood samples. Presence of a high 
number of basophils and neutrophils can be suggestive of CML. In addition, the 
samples show close to normal cell distribution in patients with acute leukemia. 
Progression of CML to blast crisis marks the final phase of the disease.  
2.2.2. Non-Coding RNAs 
In the recent years, non-coding RNAs (ncRNA) have gained the attention because of 
the potential they exhibit as a significant role in a numerous biological regulation 
(Kung, Colognori, & Lee, 2013) Scientific research has led to the discovery of 
multiple new RNA types. However, only a small class of the non-protein coding 
transcripts has shown potentially-derived functions. Transcriptomic studies have also 
developed knowledge on new classes of noncoding transcripts in various diseases. In 
a study carried out by Ponting et al.  (2009) examined the evolution and the functions 
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of the noncoding RNAs (ncRNAs). Despite being the least understood of the 
transcript species, ncRNAs have shown potential in critical areas such as transcription 
regulation, disease, and epigenetic gene regulation.  
Long non-coding RNAs (LncRNAs) are non-protein coding transcripts that are longer 
than 200 nucleotides. LncRNAs are also referred to as non-protein coding transcripts 
(Cao, 2014) In the vertebrate genomes, multiple genes encoding lncRNA have been 
discovered. In addition, it has become apparent that a larger fraction of the genome is 
represented in as exons in mature RNAs. Currently, more than 14,000 lncRNAs gene 
units in the human genome are annotated through extensive evidence (Kapusta & 
Feschotte, 2014) For a vast majority of the gene units, they present the RNA 
polymerase II transcripts. Large quantities of lncRNAs are known to occur in the 
mammalian genome. Since these lncRNAs are still under investigation, researchers 
have different approaches towards understanding them in terms of their origin, 
filtering, annotation and classification (Kapusta & Feschotte, 2014) The first 
classification of lncRNAs include the intergenic lncRNAs which do not overlap with 
known protein-coding loci, epigenic transcription, or post-transcriptional levels 
(Yang, Junjie, Sanjun, & Ma, 2017) Other categories are dependent on the specific 
class of organisms (Kapusta & Feschotte, 2014) For instance, in tetrapods, the 
lncRNAs are categorized based on the specific tissues and cell types they are in. On 
the other hand, in zebra fish and Drosophila, lncRNAs are inventoried in the whole 
animal but in different stages.  
A vast majority of the lncRNAs have been characterized based on experiments and 
assays both in vivo and in vitro for assessment of the both their functions as well as 
their evolutionary significance. Despite multiple lncRNAs having defined cellular 
functions, there is still limited information about the evolutionary path of lncRNAs 
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either at the individual level or as a group (Kapusta & Feschotte, 2014) The primary 
reason is that lncRNAs tend to have an extreme heterogeneous sequence. Based on 
various diverse mechanisms, lncRNAs play an essential role in multiple biological 
processes (X. Chen et al., 2017) Further research shows that mutations and 
dysregulations of the lncRNAs involved in both the development and progression of a 
number of complex human diseases such as colon cancer, lung cancer, cardiovascular 
diseases, Alzheimer's disease, diabetes and leukemia (X. Chen et al., 2017) The field 
of cancer research has particularly been promoted by the current advances in 
understanding the basic mechanisms on how lncRNAs cause or support cancer 
progression. The current knowledge on changes of lncRNAs is likely to open up new 
methods including lncRNA-based clinical applications in cancer research.  
Yang et al. (2017) draw attention to the importance of understanding the origins of 
lncRNAs in order to properly outline their functions and classify them accordingly. 
There are various ways in which the functional noncoding RNAs can develop. The 
first hypothesis on the origin of lncRNAs is through frame disruptions of a protein-
coding gene which leads to the generation of lncRNAs. Secondly, due to 
chromosomal re-arrangement, two untranscribed and divided sequences can be 
juxtaposed into a multi-exon lncRNA. The third hypothesis on the origin of lncRNAs 
is through duplication of the noncoding gene as a result of retro transposition. Also, it 
is thought that tandem duplication events of neighboring repeats in transcriptions can 
lead to the formation of lncRNAs (Yang et al., 2017) The last hypothesis on the origin 
of the lncRNAs suggests that a transposable element is inserted into a gene as the 
lncRNA. Despite these assumptions being used widely to describe the origin of 
lncRNAs, there is little knowledge currently to ascertain any of them. However, for 
some few transcripts such as the X-inactive specific transcript (Xist), the origin is 
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known. The lncRNAs are found in either sense or antisense alignment to protein-
coding genes. Most of the lncRNAs function in cis through their own transcription or 
through intrinsic RNA-mediated functions in trans (Cheetham, Gruhl, Mattick, & 
Dinger, 2013) Current knowledge on the clinical importance of lncRNAs is likely to 
boost understanding of most medical conditions including genetics.  
2.2.3. Functional Mechanism of LncRNAs 
Signaling molecules. A variety of lncRNA transcripts found to play a significant role 
in regulating different pathways with respect to cellular and molecular levels. 
Accordingly, lncRNAs functionally categorized into different classes. The first class 
of functional mechanism of lncRNA is the signaling molecules such as HOTAIR and 
lincRNA-p21 (Yang et al., 2017) These molecules are transcribed as a result of diverse 
stimuli in a time-or space-specific manner. These lncRNA molecules reflect the 
integrated transcriptional activity. Wang and Chang (2011) identified that lncRNAs 
usually demonstrate cell type-specific expression and response to stimuli. Thus, it is 
possible that these responses are under a transcriptional control. Furthermore, due to 
the specificity of the time and place of transcription of individual RNAs, the 
molecules are in a position to serve the signaling role efficiently. These signals are 
indicative of a response to stimuli, interpretation of the cellular context and 
integration of the cellular signals. Signaling molecules are further divided into by-
products of transcription and those possess the regulatory functions. Using the RNA 
for regulation is advantageous because the processes are performed faster without the 
need for protein translation (K. C. Wang & Chang, 2011). 
LncRNAs have been used as signals for marking space, time, expression of gene 
regulation and developmental stages. Despite having the two parental alleles 
expressed equally in some cases, there are specific subsets of genes which signal to 
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imprint. In such cases, the expression is restricted by an epigenetic mechanism 
mediated by the lncRNAs. Another signaling role of the lncRNAs is through 
mediating anatomic specific expression. LncRNAs involved in this process include 
the HOTTIP and HOTAIR.  
DNA damage also activates lncRNAs such as PANDA and lincRNA-p21 which are 
mainly detected during times of cellular stress. The signals are important for 
regulation of p53 which directly respond to DNA damage through induction of 
lincRNA-p21. Another area where lncRNAs are known to signal for DNA damage is 
in the mammalian CDKNIA promoter whereby several lncRNAs such as PANDA are 
produced and transcribed following DNA damage. During the process, PANDA is 
activated by the p53 binding to the CDKNIA locus. Once produced, PANDA interacts 
with the transcription factor NF-YA in order to limit expression of pro-apoptotic 
genes thus contributing towards cell cycle arrest. The mechanism demonstrates that 
several lncRNAs are potentially useful in cell-growth control. The signaling role of 
lncRNAs is also critical in coordinating cellular activities. These lncRNAs have 
enhancer-like functions in various human cell lines. Studies have shown that depletion 
of these lncRNAs resulted in decreased expression of the neighboring protein-coding 
genes. The activity of master regulatory genes in the process of cell differentiation is 
also affected. Wang and Chang (2011) described the activity of classical enhancers of 
lncRNAs as orientation dependent. In addition, this class of lncRNAs requires a 
minimal promoter in the target gene for transcription enhancement. Lastly, lncRNAs 
such as staufen and RNA-decay are important signaling molecules for repeated 
sequences. Thus, signal molecules of lncRNA are not only used as markers for 
downstream transcriptional elements, but they are also crucial in detection and 
identification of transcript abundances in terms of repetitions.  
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Molecular decoys. The second class comprises of molecular decoys such as PTENP1, 
MALAT1, PANDA and IPS1 (Yang et al., 2017) These molecular decoys have a role 
in binding and competitively inhibiting the transcription factor miRNAs. lncRNAs 
which act as molecular decoys regulate the process of transcription by binding the 
protein target. Therefore, the molecular decoys act as negatively regulating an effector 
without exerting additional functions. An example of lncRNA gene in the human 
which possess the RNA dependent mechanism of transcriptional repression is the 
DHFR. The gene directly inhibits the assembly of the pre-initiation complex through 
the formation of a stable ncRNA-DNA complex (K. C. Wang & Chang, 2011).  
TERRA is another lncRNA which is thought to have a role in regulation and 
protection of the chromosome ends. Wang and Chang (2011) pointed out that the 
telomere is a key DNA-protein complex found at the end of the eukaryotic 
chromosomes which enhances the stability of the chromosome. Another way in which 
TERRA performs the regulatory role is through level changing in a cell cycle-
dependent manner (K. C. Wang & Chang, 2011) The levels tend to increase in the 
early G1 and later decrease in the S phase. During the transition phase, TERRA 
reaches the lowest expression levels especially between late S and G2. In addition to 
that, Wang and Chang (2011) stated that down-regulation of TERRA in the S phase is 
vital in releasing telomerase and allows the telomeric strand to extend. Another 
lncRNA which possesses the decoy function is the PANDA-NF-YA (K. C. Wang & 
Chang, 2011) Once the DNA is damaged, and cell arrest or apoptosis is initiated, 
expression of PANDA is induced temporarily to inhibit the apoptotic genes from 
expression to promote the survival of the cell. Studies are done to assess the decoy 
function of PANDA show that its depletion increases the level of NE-YA occupancy at 
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the target genes. On the other hand, elimination of both PANDA and NE-YA attenuates 
the induction of apoptosis and the expression of the apoptotic gene.  
Wang and Chang (2011) suggested that the lncRNA decoys are important especially 
when functioning in the nuclear subdomains or in the cytoplasm. MALAT1, an 
abundant nuclear lncRNA found in the mammalian cells binds to the serine/arginine 
splicing factors thus altering the activity of pre-mRNAs. MALAT1 has a particularly 
important role in the hippocampal neurons whereby it regulates serine splicing factors 
resulting in the formation of a synapse (K. C. Wang & Chang, 2011). 
Molecular guides. The other class of lncRNA based on their functional mechanism is 
the molecular guides. Examples of these lncRNAs are Xist, HOTAIR, COLDAIR, and 
lincRNA-p21 (Yang et al., 2017) The molecular guides recruit chromatin-modifying 
enzymes to various target sequences in either cis or trans. The manner in which the 
RNAs perform the role cannot be predicted easily based on the lncRNA sequence. 
There are multiple ways in which the molecular guide lncRNAs function in the 
process of transcriptional regulation. For example, Enhancer RNA (eRNA) and Air 
tend to exert their effect in cis (K. C. Wang & Chang, 2011) On the other hand, 
lncRNAs like HOTAIR and lincRNA-p21 which takes complex forms in the regulation 
require additional ability to interact with other factors to be effective. For the 
molecular guides, the gene regulatory components which are carried on by the 
lncRNA include the activating complexes and the repressive complexes (K. C. Wang 
& Chang, 2011) The basic mechanisms in which the lncRNAs work is based on the 
assumption that proper localization of the effector molecule is changed as a result of 
knockdown of the lncRNA. Another possible event following the knockout includes 
loss of function of the effector. Also, a knockdown on both the effector and the 
lncRNA can exacerbate the phenotype (K. C. Wang & Chang, 2011).  
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 Wang and Chang (2011) categorized the molecular guide RNAs based on their 
course of action in transcriptive regulation. For example, some of the known 
molecular guides in cis include the CCND1, HOTTIP, Xist, rDNA, Air and COLDAIR 
transcripts. On the other hand, the molecular guides in trans include the other PRC2-
bound RNAs, HOTAIR, Jpx, and linc-2. The long noncoding RNA Air silences the 
transcription of the target gene on the paternal chromosome through interaction 
between the chromatin, its ncRNA, and the promoter. Also, the ability of the RNA to 
bind to the complementary strands of DNA sequences may be an indicator of the 
RNA’s capability to guide on the transmission of chromatin (K. C. Wang & Chang, 
2011). Another aspect to the cis-regulation by the lncRNAs is the identification of 
HOTTIP lncRNA. HOTTIP serves as an intermediate for transmission of information 
from a higher order chromosomal looping to chromatin modification.   
Molecular scaffolds. Finally, the molecular scaffolds ANRIL, TERC, and HOTAIR are 
important in assembling proteins to form ribonucleoprotein complexes. The property 
of lncRNAs to act as molecular scaffolds is critical to the precise control of the 
specificity and dynamicity of intermolecular interactions and the signaling events. 
Wang and Chang (2011) pointed out that there is a possibility of lncRNAs to play a 
role in various scaffolding complexes despite this being traditionally known as a 
function of the proteins. Molecular scaffold presents the most complex class of 
lncRNAs. They have various domains which bind distinct effector molecules (K. C. 
Wang & Chang, 2011) This property of molecular scaffolds enables them to bind to 
multiple effector partners simultaneously. Further knowledge of scaffolding 
complexes is critical in understanding the specific signaling components and how 
they impact on the cellular behavior.  
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A major hypothesis on the how the molecular scaffold work suggest that knockdown 
of the lncRNA changes or interferes with the localization of the effector molecule (K. 
C. Wang & Chang, 2011) In addition, disassembling the lncRNA-effector scaffold 
may lead to loss of function of the component effector. Molecular scaffolds such as 
ANRIl and HOTAIR represent lncRNAs which are present all the time at the locus and 
recruit sets of chromatin modifying complexes to the gene responsible for silencing 
(K. C. Wang & Chang, 2011) Therefore, they indirectly modulate the transcriptional 
activities.  
2.2.4. Integrated Functions 
Despite the functional mechanisms which facilitate their classification, lncRNAs have 
multiple modes of action which are useful in promoting their biological functions. 
LncRNAs also play an important role in modulating the activity of protein-binding 
partners (Wilusz, Sunwoo, & Spector, 2009) Many proteins, through the available 
motifs, bind to RNAs in order to modulate localization, processing and the stability of 
the bound RNAs. lncRNAs act as co-activators of proteins which are used in the 
process of transcriptional regulation (Wilusz et al., 2009) Another way in which the 
lncRNAs modulate the activity of protein-binding partners is by regulating their 
subcellular localizations. During the process, the transcription factor NFAT is 
localized in the cytoplasm until it is imported to the nucleus for transcription of the 
target genes.  
Wilusz et al. (2009) in their recent studies suggested that lncRNAs are precursors for 
small RNAs. Normally, small RNAs usually cluster near the 5' and 3' ends of the 
gene. Post-transcriptional processing of lncRNAs and protein-coding RNAs produce 
many small RNAs with a 5' cap structure (Wilusz et al., 2009) In addition, lncRNAs 
affect the processing of other RNAs. For instance, they are known to modulate the 
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ability of other RNAs to be cut into small RNAs. Also, lncRNAs affect the processing 
by changing the pre-mRNA splicing patterns (Wilusz et al., 2009) Furthermore, it is 
possible for various forms of lncRNAs to base-pair with small RNAs in order to 
modulate their activities. An example is when lncRNA molecules interact with 
miRNAs. As a result of competitive inhibition, miRNAs are unable to bind with their 
target mRNAs (Wilusz et al., 2009). 
2.2.5. LncRNAs Pathways in Cancer 
Cancer being a disease of aberrant gene expression, it is important to understand 
mechanisms of gene dysregulation and how they contribute to malignancies. 
Cheetham et al. (2013) identified the inheritable single-gene disorders contribute to a 
small percentage of all cancers. On the other hand, a majority of the cancers arise 
from somatic mutations as a result of interaction between various genetic and 
environmental factors. With the discovery of multiple non-coding genes including the 
lncRNAs has revolutionized the current understanding of how the cell's mutation 
leading to cancer development. In addition, the knowledge has contributed especially 
in the development of new therapeutic options for specific carcinomas. However, 
studies on the specific pathway of lncRNAs are still in progress. The current 
knowledge of the disease is based on a predictive framework used to evaluate the 
expression patterns of genes (transcripts) and how they affect cellular function 
(Schmitt & Chang, 2016) Given the extensive role that lncRNAs play in the cell, it is, 
therefore, possible to predict their involvement in various cancer pathways.  
Research showed that various lncRNAs have the potential to signal for specific states 
of the cell especially in case of pathologies like cancer. Different molecules of 
lncRNAs signal for specific cellular need. For example, Schmitt and Chang (2016) 
associated the overexpression of HOTAIR, a type of lncRNA with the prediction of 
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the presence of progressive metastatic disease in patients who had surgically resected 
breast cancer. In addition, further studies done on lncRNA HOTAIR have shown that 
it can predict differential sensitivity among patients with ovarian cancer. As a result, 
the findings are helpful especially in guiding the clinical decisions among the health 
care providers. Other forms of lncRNAs are critical in the development of diagnostic 
methods for cancers. Schmitt and Chang (2016) assessed the role of PCA3 which is 
useful in PSA procedure for prostate cancer diagnosis. The test is based on lncRNAs 
and has become popular due to its non-invasive nature.  
Another cancer pathway where the use of lncRNAs is extensive is on the 
identification of cancer subtypes which are clinically relevant. For example, an 
increased chance of developing metastatic progression of prostate cancer among men 
can be predicted by the overexpression of SChLAP. Additionally, some lncRNAs are 
extensively used to predict the effectiveness of various cancer therapies. For instance, 
studies have shown that ovarian cancer patients who show expression of HOTAIR 
after carboplatin treatment have poor survival rates (Schmitt & Chang, 2016; Zhao et 
al., 2016).  
 In a related study, Zhao et al. (2016) break down the various pathways in cancer 
development where the lncRNAs are heavily involved. Among them is the epigenetic 
regulation in cancer development. Modification of the cancer-associated RNAs is 
known to result in loss of imprinting. Alternatively, the lncRNAs can also contribute 
to epigenetic modification or the functional genes themselves. As a result, these 
changes can either cause or prevent diseases (Zhao et al., 2016) LncRNAs interact 
with the nucleosome remodeling complex in the cells and contribute in either the 
dislocation or rearrangement of the nucleosome. Consequently, repositioned 
nucleosome can be repackaged in regions which contain tumor suppressor genes and 
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subsequent repression leading to cancer development (Zhao et al., 2016) A good 
example is the lncRNA HNF1A-AS1 whereby recent studies have demonstrated its 
involvement in esophageal tumorgenesis as a result of the role it plays in modulating 
the chromatin and assembly of the chromosome. Epigenetic regulation of lncRNAs in 
cancer development can also take the form of histone modification. In this case, the 
lncRNAs are involved in the recruitment of histone modifying enzymes in the cis 
function at the site of transcription. An example is the CTBP1-AS in prostate cancer. 
The lncRNA acts in cis and trans to regulate the epigenetic network thus stimulating 
cell proliferation (Zhao et al., 2016) Lastly, epigenetic regulation of lncRNAs in 
cancer can occur through DNA methylation. LncRNAs are involved in the 
recruitment of DNA methyl-transferases thus inducing demethylation. As a result, the 
tumor suppressor genes in the cell are silenced contributing to cancer pathogenesis. 
Although the process is not yet well understood, it is hypothesized that lncRNAs 
interact with the DNA methyl-transferases. Thus, the new complex guides the protein 
to various sites resulting in methylation of the promoters and subsequent silencing of 
the tumor suppressor genes (Zhao et al., 2016). 
Zhao et al. (2016) further suggested that lncRNA genes (transcripts) can contribute to 
cancer development through regulation of the transcription pathway. The process 
involves the regulation of the transcriptional factors and polymerases. The level of 
transcription which is mediated by the lncRNAs is dependent on a number of factors 
such as the sequence features of the lncRNAs and their relative position. In addition, 
the target gene to be regulated also affects the level of transcription. During early and 
metastatic phase of the breast cancer, lncRNA HOTAIR is overexpressed and interacts 
with enzymes lysine-specific demethylase 1A and polycomb repressive complex 2 
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(PRC2) to control methylation process and subsequently regulating gene expression 
(Zhao et al., 2016). 
LncRNAs also act in posttranscriptional regulation to cause cancer. Interaction with 
complementary base pairs with the antisense lncRNA transcripts forms RNA dimers. 
This binding resulting in blocks all the binding sites for the transcription factors while 
promoting those affecting posttranscriptional processes such as transport, ncRNA 
splicing, degradation, and translation. An example of lncRNA which causes cancer 
through posttranscriptional regulation pathway is the MALAT1. It regulates splicing of 
mRNAs through modulation of serine/arginine splicing factors.  
Signaling pathways regulation by the lncRNAs is another important mechanism by 
which they contribute to cancer pathogenesis. Although the exact process is not yet 
understood, lncRNA can either suppress or activate the transduction pathway of the 
signals either at the transcription or posttranscriptional level (Zhao et al., 2016) There 
are many signaling pathways which are mediated by the lncRNAs to cause cancer. 
For instance, the ERK/MAPK pathway affects the important processes of the cell 
formation leading to unregulated cell growth. The lncRNA contributes to cancer 
progression by sending signals in the cell to boost its ability to escape apoptosis, 
enhancing immortalization.  
Another signaling pathway through which lncRNAs cause cancer is Wnt/β-catenin 
signaling pathway which is essential in regulating proto-oncogene β-catenin stability 
(Zhao et al., 2016) Studies have revealed that the gene is activated in various types of 
cancers. The pathway is evolutionary conserved and it critical in cell proliferation 
regulation. In addition, the proto-oncogene controls tumor regression activity. 
Therefore, activation of the Wnt/β-catenin pathway results in genetic alteration and 
cancers. An example of lncRNA which has recently been associated with cancers 
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through the Wnt/β-catenin pathway is lncRNA HOTAIR. It plays a significant role in 
the development of squamous cell carcinoma. The pathway is activated following 
overexpression of the HOTAIR and PRC2. Activation of the Wnt/β-catenin pathway 
induces esophageal squamous cell carcinoma (ESCC) metastasis. Other examples of 
lncRNAs which are associated with various cancer types include UCA1/Wnt6 in 
bladder cancer (Zhao et al., 2016). 
Another pathway in cancer development is the AKT signaling pathway whereby 
serine-threonine; Akt kinases affect the signaling network. It is vital in areas such as 
apoptosis, differentiation, migration, metabolism, and proliferation (Zhao et al., 
2016).  
Another lncRNA which is common in promoting tumor growth and metastasis is 
MALAT1. The lncRNA is involved in a number of pathways all of which lead to 
cancer development (Zhao et al., 2016) For example, in gallbladder carcinoma, 
suppression of MALAT1 inactivates the ERK/MAPH pathway. The new findings are 
indicative of the role that MALAT1 plays a role in the proliferation of metastasis. 
Example of cancer diseases that develops as a result of direct involvement of 
lncRNAs is the hepatocellular carcinoma (HCC). Studies done on this cancer type has 
shown high levels of lncRNA URHC which plays a role in signaling and regulation of 
apoptosis.  
Zhao et al. (2016) also described the p53 signaling pathway which is activated as a 
result of cellular stress including oncologic signaling and DNA damage. The process 
then mediates the gene transcription. lncRNAs have been identified as part of the p53 
in these transcriptions. An example of lncRNA in this pathway which has been 
associated with cancer development is lincRNA-Pint. The lncRNA interacts with 
PRC2 to form a p53 transcriptional target. As opposed to most lncRNAs, lincRNA-
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Pint is a tumor suppressor. In most, colorectal cancer studies, the level of lincRNA-
Pint is usually downregulated. Protein stability is also important in suppressing 
cancers. Therefore, some lncRNAs such as p21 act via trans gene regulation to 
repress the genes which are useful in regulating the stability including p53 (Zhao et 
al., 2016). 
In the ATM-CHK2 signaling pathway, the core role of the lncRNAs is in the 
regulation of the cell cycle. As a result, the process corresponds to DNA damage 
signals and subsequent tumor growth. On the other hand, STAT3 signaling pathway 
through the cell cycle induced prevention of important cellular activities such as 
apoptosis, and subsequent development of cancerous cells (Zhao et al., 2016) In 
PI3K/AKT signaling pathway, lncRNA HOXD-AS1 is subjected to morphogenic 
regulation as a result of activation this pathway which develop the oncogenic 
pathways. Also In this process, lncRNA UCA1 is expressed in bladder cancer. In such 
cases, there is a high rate of cell proliferation as well as regulation of the cell cycle 
progression through CREB activation. Finally, the TGF- β signaling pathway has a 
cytokine transforming growth factor β which is multifunctional. These factors are 
significant in inducing cell-cycle and tumorigenesis (Zhao et al., 2016). 
Studies have been shown that various forms of cancers such as hepatocellular 
carcinoma are induced through TGF- β signaling pathway which is considered as a 
complex process. Studies have shown that in some rare cases, as cancer progresses, 
some forms of lncRNAs are used in regulating the signal transduction pathways (Zhao 
et al., 2016) In addition, the lncRNA is used as the downstream pathway. As a result, 
it forms a positive and negative feedback loop. 
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Table 1. Listed the LncRNAs expression profiling associated with cancers (Schmitt & 
Chang, 2016) and (Yang et al., 2017). 
 
LncRNAs Expression Patterns Transcript function 
HOTAIR 
Upregulated in breast cancer/Ovarian 
cancer 
Tumor oncogene 
PTCSC3 Downregulated in thyroid cancer Tumor suppressor gene 
ANRIL Upregulated in prostate cancer 
The scaffold in mediating 
transcriptional silencing of 
INK4b-ARF-INK4a 
XIST Dysregulated in multiple types of cancer 
The effector of the X 
inactivation process 
PRNCRI Upregulated in prostate cancer Tumor suppressor 
HULC Upregulated in hepatocellular carcinoma Tumor suppressor 
H19 Upregulated in hepatocellular carcinoma Tumor suppressor 
KCNQ1OT1 Upregulated in colorectal cancer 
Signaling for polycomb 
repressive complex 2 (PRC2) 
 
 
2.2.6. The Clinical Implication of LncRNAs in CML 
Li and Wang (2016) stated that CML is among the malignant diseases occurring in the 
clonal hematopoietic stem cells. The specific marker of CML is the breakpoint cluster 
BCR/ABL1 fusion gene and the Philadelphia chromosome (Kurzrock, Kantarjian, 
Druker, & Talpaz, 2003) Tumorigenesis induced by the BCR/ABL1 fusion gene 
involves alteration of various signaling pathways with the aim of facilitating and 
regulating cell survival and proliferation (Ying Li & Wang, 2016) PI3K/Phosphatase, 
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tensin homolog RAS and Janus Kinases are among the enzymes produced and act both 
as the signal transducers and activators of the transcription factors. Further studies on 
CML have shown that in cases of alteration of BCR-ABL1 gene expression, the 
processes of inducing cellular proliferation are upregulated. Other processes which 
are downgraded include inhibited cellular differentiation as well as apoptosis. Li and 
Wang (2016) pointed out that one of the key regulators of cellular transformation 
medicated by BCR-ABL1 is lncRNA BGL3. It has a role in the cell whereby it acts as 
a competitive endogenous RNA for repressing PTEN mRNA and at the same time 
binding with miRNAs (Ying Li & Wang, 2016) examples of miRNAs in which BGL3 
binds to including miR-93, miR-17, miR-20b, miR-106a, and miR-106b. Once bound, 
BGL3 cross-regulates the expression of PTEN. Li and Wang (2016) pointed out that 
inhibition of BCR-ABL1 kinase activity induces the expression of lncRNA BGL3. 
Furthermore, its expression can be induced by following the disruption of BCR-ABL1 
expression in either leukemia cells or K562 cells among CML patients (Ying Li & 
Wang, 2016) Using c-Myc-dependent DNA methylation, BCR-ABL1 is also capable 
of downgrading the expression of BGL3. It is, therefore, possible to develop a 
potential therapeutic strategy for CML through regulation of lncRNA BGL3.  
Several studies have demonstrated the significant role which lncRNAs play in various 
biological processes including the development and progression of the CML. The 
primary difference between lncRNAs and other protein-coding genes including 
miRNA is that they are not yet well understood on their specific roles (Ying Li & 
Wang, 2016) LncRNAs contribute to the carcinogenesis through disruption of the 
major biological processes. The most common processes disrupted by the lncRNA are 
chains resulting to cancer development include gene silencing, and DNA methylation 
in epigenetic modifications (Kukurba & Montgomery, 2015) The main limiting factor 
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in understanding the specific role of the lncRNAs in the development of CML is lack 
of sufficient studies on all the lncRNAs involved. Only some of them has been 
identified so far (Ying Li & Wang, 2016) As a result, this has presented major 
challenges in fully investigating both their functions and mechanisms. Li and Wang 
(2016) highlighted that the differential expression of lncRNAs will provide an 
important marker in diagnosing and prognosis of CML in the future. Also, further 
research in future will be imperative in the development of lncRNA-mediated 
therapies.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1. Ethical Approval 
Samples were utilized as part of ethical approval by HMC Ethics Committee of 
Medical Research Centre (MRC) at Hamad Medical Corporation- HMC. Copies of 
ethical approval with a study 11118/11 and MRC-03-17-0052 are attached in the 
appendix. 
3.2. Sample Size and Collection 
A total of 16 blood samples were used for this study that included nine samples of 
chronic phase (CP), three samples of complete remission (CR) and four samples of 
healthy individuals (CNT) The samples of the study subjects were collected based on 
the inclusion and exclusion criteria illustrated in Table 3.Whole blood has been used 
from each patient for RNA isolation by using QIAamp RNA Blood Mini Kit-based 
enzymatic reactions. Blood was mixed with erythrocyte lysis buffer (EL) twice: First, 
by adding 5:1 volumes of (EL: blood) with cold incubation for 15min followed by the 
centrifugation at 4000 rpm for 5min at 4°C Second, by adding 2:1 volumes of (EL: 
blood) followed by the centrifugation at 4000 rpm for 5min at 4°C to have a clear 
supernatant from RBCs and a good precipitated cell pellet (PBMCs) in which the 
intact RNA was isolated using RLT buffer (lysate) per sample which was stored at -80 
for later use. Similarly was done for the control groups. The method for RNA 
extraction is described below in detail and illustrated in figure 2. 
RNA extraction was performed at the molecular diagnostic laboratory at Hamad 
Medical Corporation-HMC. RNA was extracted from peripheral blood samples 
(PBMCs) as follow: Manual method was used for RNA extraction by following the 
manufacturer’s instructions of ―QIAamp RNA Blood Mini Kit‖ supplied by 
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―QIAGEN‖. For unhealthy blood (High WBCs count leukemic patients) reduce the 
blood volume to <1. 5ml a maximum of 1x10
7 
leukocytes should be processed while 
for healthy blood a maximum of 1. 5ml is required which contains 4x10
3
-7x10
3/μl. 
Whole blood was mixed with erythrocyte lysis buffer (EL) at a ratio of 5:1 (V/V) 
using 15ml falcon tube which incubated in ice for 15 minutes with brief vortex two 
times (every 5 minutes) during incubation to have a translucent and clear cell 
suspension, then centrifugation at 4000 RPM for 5 minutes at 4°C followed by 
decanting the supernatant and reserving the pellet. Add 2 volumes of EL buffer to 1 
volume of the whole blood added initially, then cell pellet resuspended by vortexing 
and then centrifugation for 5 minutes at 4000 RPM at 4°C. 
For homogenization step, 1ml of RLT buffer was mixed with 10μl of β -
Mercaptoethanol (β-ME) then from this mixture (350μl or 600μl) of RLT buffer was 
added to the leukocyte pellet then lysate was pipetted into QIAshredder spin column 
in a 2ml collection tube and centrifuged for 2 minutes. The spin column was 
discarded and the resulted lysate was kept in collection tube either could be stored at -
80°C for later using. Based on RLT volume added initially so one volume (350μl or 
600μl) of 70% cold ethanol added to the lysate and mixed by gentle pipetting. 
New QIAamp spin column in 2ml collection tube was used and centrifuged for 1 
minute at 10,000 RPM, here the maximum volume should be added is 700μl. If the 
sample volume exceeding 700μl, divide this step into two steps after that the QIAamp 
spin column was transferred into a new collection tube followed by the addition of 
500μl of RW1 buffer to the QIAamp spin column and centrifuged for 10 minutes at 
10, 000 RPM. QIAamp spin column was placed in a new collection tube and 500μl of 
RPE buffer was added and the tube was kept in the rack for 1 minute at room 
temperature then centrifuged for 3 minutes at 10, 000 RPM. A final 1.5 ml 
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microcentrifuge tube was labeled with sample lab number in which QIAamp spin 
column was transferred to it and 30- 50μl of RNase-free was added into the QIAamp 
membrane which kept for 1 minute at room temperature followed by centrifugation 
for another 1 minute, at 10,000 RPM thus eluted samples were resulted for RNA 
quantity and quality assessment. 
The Concentration and purity of the extracted RNA were measured by the 
NanoDrop™ (instrument, Thermo Scientific). The concentration of RNA was 
measured at absorbance ratio of 260/280, which is the acceptable purity ratio of 
nucleic acid against proteins that range from (1.8-2.2). Simultaneously, the RNA 
purity was measured at another absorbance ratio of 260/230 which indicates the 
nucleic acid purity against remained ethanol in the eluted sample, preferably it 
required >1.7 for this ratio. The optimum volume required per sample for accurate 
measurement is 2μl.  
The RNA concentration was adjusted to 40ng/12ul of that was sent for RNA- 
Sequencing to the Genomics-core laboratory of Weil Cornell Medical School in 
Qatar.  
In addition to that, RNA integrity number (RIN) was assessed using Agilent 2100 
Bioanalyzer system which is important step prior to gene expression analysis, the 
analysis based on measuring the RNA degradation which usually occur when there is 
a decrease in the 18S and 28S ribosomal band ratio observed when performing gel 
electrophoresis and an increase in baseline signal between the two ribosomal peaks 
because the expression of the ribosomal rRNA is about 30% of total RNA. (Mueller, 
Lightfoot, & Schroeder, 2004) RIN assessment was done at the Genomics-core 
laboratory of Weil Cornell Medical School in Qatar. The RNA integrity number 
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(RIN) values for a set of eight samples were consistently ≥ 8.10 and the RIN values 
for the other set of eight samples were ≤ 5.90 but all samples were library constructed 
and sequenced. 
Table 2. The characteristics of the study subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients 
 
Age (year) 
 
Gender 
 
CML phase 
  
CP1 57 M 
Chronic Phase 
 
  
CP2 58 M 
Chronic Phase 
 
  
CP3 30 F 
Chronic Phase 
 
  
CP4 59 M 
Chronic Phase 
 
  
CP5 36 M Chronic Phase   
CP6 66 M Chronic Phase   
CP7 42 M Chronic Phase   
CP8 22 M Chronic Phase   
CP9 30 F Chronic Phase   
CR1 37 M Complete remission   
CR2 40 M Complete remission   
CR3 61 M Complete remission   
CR4 34 M Complete remission   
CNT1 40 M Healthy Individual   
CNT4 30 F Healthy Individual 
  
CNT5 30 F Healthy Individual 
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Table 3. The inclusion and exclusion criteria of the study subject. 
Inclusion Criteria Exclusion Criteria 
Patient’s aged ≥ 20 years old 
 
Normal WBCs count considered at 
4-7X10
3
 with exception of the Control group 
 
Hematologic, Cytogenetic and Molecular -
based diagnosis at any phase of CML 
 
 
Ph chromosome-negative,BCR-ABL1 
negative CML 
WBCs count>10X10
3
, Ph chromosome-
positive CML, BCR-ABL1 ratio (0% - 100%) 
Hematology, Cytogenetic and Molecular 
results 
Previous history of IM intolerance 
 
Imatinib Mesylate dose: 400mg/day, 
Nilotinib dose: 200mg/day (Alternative to 
(IM, Oral medications) 
 
 
Pregnant or breastfeeding patients 
Treatment response degree: Optimal response 
or resistance (treatment failure) 
 
 
Patients able to take an oral daily capsule 
 
 
Patients follow-up every three months,  
WHO and ELN-based guidelines 
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3.2.1. RNA Extraction and Purification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           
Figure 2. Flowchart of RNA extraction and purification.                      
<1.5ml of patients’ blood were 
collected in EDTA tube and RNA 
extracted using QIAamp RNA Blood 
mini kit-Qiagen 
Whole blood mixed with EL buffer 
by adding 5:1 volumes of (EL: 
blood) for RBCs lysis 
Cell pellet (Leukocytes) lysed by 
adding 350-600μl RLT+ β –
Mercaptoethanol (Lysate) containing 
isolated RNA used in the same day or 
stored at -80C for later use 
Homogenisation using QIAshredder 
spin column followed by adding 350-
600μl of 70% ethanol to 
homogenised lysate 
Total RNA will bind to QIAamp 
membrane 
Wash 3X: one wash by adding 
700μl of RW1 wash buffer and 
2X by adding 500μl in each 
using RPE wash buffer 
Centrifuge at 10,000rpm for 15s 
after each washing step 
 
Add 30-50μl of RNase free 
water to QIAamp spin column in 
1.5ml microcentrifuge tube 
Centrifuge at 10,000rpm for 
1min for (elution) 
Eluted RNA ready for quantity 
and purity assessment 
 RNA Concentration measured 
at absorbance ratio of 260/280 
and the purity ˃1.7 was 
considered using Nanodrop ™-
Thermo Scientific 
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3.3. RNA-Sequencing (RNA-Seq) 
All RNA transcripts (coding and noncoding) longer than 170 bp were sequenced by a 
total of 1 Gb reads, 10X coverage, paired-end sequencing of 100 bp usingHiseq 
Illumina 4000. (Paired-end sequencing enable the sequencing of both sides of the 
DNA fragment in forward and reverse directions because the distance between each 
paired read is known which can be used for alignment to map the reads over the 
repetitive regions precisely leading to better alignment of the reads especially across 
difficult to sequence repetitive regions and improve the quality of the reads. 
3.4. Preparing Raw Data 
Fastq files of paired reads were imported into CLC Biomedical Genomics Workbench 
v5. Following the quality control (QC) of the reads which performed using the QC for 
sequencing reads tool integrated into CLC Biomedical Genomics Workbench 
software then reads were trimmed and overlapping paired read were merged into one 
sequence read, whenever relevant.  
3.5. RNA-Sequencing Analysis  
Paired reads were used to perform RNA-sequencing analysis followed by a 
calculation to create the fold change based on an annotated reference genome.  
3.6. Map Reads to Reference 
Reads were mapped to reference database using the following settings. To improve 
mapping the ―quality score‖ was set at 10 for matching score. Other values were used 
as default. Reads shorter than 15 bps and less than half with 80% similarity were not 
mapped. For paired distance 100,000 reads were randomly extracted from the full data 
and mapped against the reference sequence (Homo_sapiens_refseq_GRCh38.p11) 
using alignment parameter tool integrated within the CLC Biomedical Genomics 
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Workbench software in which the QC of mapping criteria were determined. Mapped 
reads were counted and their distribution across genes and transcripts were calculated 
(Mortazavi, Williams, McCue, Schaeffer, & Wold, 2008) First, all genes are extracted 
from the reference genome (Homo_sapiens_refseq_GRCh38. p11_ Genes). Next, all 
annotated transcripts are extracted from (Homo_sapiens_refseq_GRCh38. p11_ 
mRNA). If there were several annotated splice variants, they all were extracted and 
kept for downstream analysis.  
3.7. Local Realignment 
To improve the alignments of the reads in an existing read mapping a realignment 
step was used in areas around insertions and deletions relative to the reference 
(Homer & Nelson, 2010) In this step reads mapped with one end of the read on one 
side of the insertion-deletion (indel) and the rest mapped on the other side. It used 
information from the other reads mapping to a region containing an indel, including 
reads that are located more centered across the indel and thus have been mapped with 
ends on either side of the indel. 
The following steps were taken to normalize the data in order to minimize any 
differences due to sequencing depth (the number of the unique sequence (reads) 
shared the same region in a given reference sequence). 
3.8. Count Normalization 
To remove the possibility of any differences between samples resulted from possible 
differences in sequencing depth, a TMM (trimmed mean of M values) normalization, 
similar to that in the empirical analysis of digital gene expression R (EdgeR) was 
performed prior to comparing of samples (Robinson & Oshlack, 2010). 
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TMM normalization adjusts library sizes based on the assumption that most genes are 
not differentially expressed. For the expression visualization tools, (Create Heat Map 
and PCA) additional filtering and normalization are performed as followings: 1) 'log 
CPM' (Counts per Million) values are calculated for each gene. 2) The CPM 
calculation uses the effective library sizes as calculated by the TMM normalization. 3) 
After this first normalization, a second one is performed for each gene across samples: 
the read counts for each gene are mean centered and scaled to unit variance. 4) Genes 
or transcripts with zero expression across all samples or invalid values (NaN or +/- 
Infinity) were removed.  
3.9. Annotation with Genes and Transcripts 
The reference sequence, gene, and mRNA (included the splicing) were used for 
annotation. Expression values, RPKM and TPM were calculated using the lengths of 
the transcripts calculated from the mRNA track. No spike-in controls were used for 
this analysis. Reads that matches equally well to more than 10 hits were considered 
not unique and were not mapped. However, those reads that matched to multiple 
distinct places, but less than 10 were randomly assigned to one of these places using 
Expectation-Maximization (EM) algorithm that is similar to RSEM (software package 
used to measure the transcript quantity and expression level from RNA-sequencing 
data accurately) (B. Li & Dewey, 2011) and eXpress methods (another application 
used to quantify the data resulted from RNA-sequencing by using streaming 
algorithm with linear run time) (Roberts A, 2012) It iteratively estimates the 
abundance of transcripts, and assigns reads to transcripts according to these 
abundances.  
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3.10. Calculating Expression Values 
Each intact paired read was counted as one and was used to calculate fragments 
(FPKM) rather than mapped individual 'reads' (RPKM). The expression value was 
calculated per gene or transcript. Total counts were calculated for transcripts were the 
total number of reads mapped per transcript and for genes, the total number of reads 
mapped per gene.  
The biotypes are "as a percentage of all transcripts" or "as a percentage of all genes". 
For a poly-A enrichment experiment, it is expected that the majority of reads 
correspond to protein-coding regions. For rRNA depletion protocol, a variety of non-
coding RNA regions may also be observed. The percentage of reads mapping to 
rRNA should usually be <15% 
3.11. Calculating Fold Change  
For each gene or transcript, the ratio of the expression value in each group was 
compared to the expression value of the same gene in the control group.  
Fold change cut off was set to 1.5 for the raw count. To reduce the false positive, 
assuming that the large values in fold change can occur by chance if the expression 
levels are very low in both samples, reads with a minimum expression level of 10 or 
above were included.  
3.12. Principal Component Analysis (PCA)  
Principal Component Analysis was used to identify the outlying samples for quality 
control by reducing the number of transcripts into two or three principle components. 
Also used to examine if the selected subset of the transcripts can explain the variation 
between the groups, means that whether these transcripts in 16 samples could be 
grouped into their clinical stages The first principal component (PC1) specifies the 
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direction with the largest variability in the data between CP and CNT, the second 
component (PC2) is the direction with the second largest variation between CP and 
CR. Principal component analysis (PCA) was calculated based on the normalized log 
of count per million (CPM) and on a Pearson correlation matrix. To identify 
differentially expressed transcripts between 16 samples and 3 study groups, statistical 
analyses were done on the square-root transformed CPM of each transcript. Analysis 
of variance (ANOVA) was done to examine whether the samples or their groups or 
their interactions significantly influenced CPM. The Bonferroni correction was used 
for multiple comparison correction. Shapiro-Wilk and Bartlett’s tests were used to test 
for normal distribution of the data and homogeneity of variances (normalization), 
respectively. None of the transcript expression levels violated the assumptions of the 
normal distribution or homogeneity of variances after Bonferroni correction.  
3.13. Differential Expression 
Multi-factorial statistics, based on a negative binomial generalized linear model 
(GLM) was used to calculate differential expression in paired groups. Each gene was 
modeled by a separate GLM to fit curves of expression values without assuming that 
the error on the values is normally distributed. Similarly to the empirical analysis of 
digital gene expression R (EdgeR) and DESeq, we assume that the read counts follow 
a negative binomial distribution similar to `Gamma-Poisson', where the Poisson 
parameter λ is itself Gamma-distributed. This Gamma distribution is controlled by the 
dispersion parameter, such that the negative binomial distribution reduces to a Poisson 
distribution when the dispersion is zero. To correct the problem associated with low 
GLM dispersion for a gene Cox-Reid adjusted likelihood, as in the multi-factorial 
EdgeR method was used (Robinson & Oshlack, 2010). Finally, after GLM fit and 
dispersion the total likelihood of the model given the data, and the uncertainty on each 
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fitted coefficient was calculated to test if a given coefficient is non-zero, Wald test 
was used for all group pairs and against control group comparisons.  
3.14. Heatmap 
Heat Map was created using the TMM normalization (as described before) to make 
samples comparable, followed by z-score normalization to make transcripts 
comparable. It also simultaneously clustered samples and features. Each column 
corresponds to one sample while each row corresponds to a feature (a gene or a 
transcript) Euclidean distance was used to measure the ordinary distance between two 
points and data were further filtered by setting the minimum absolute fold change to 
1.5 and FDR p-value to less than 0. 01  
3.15. Statistical Analysis 
Statistical analysis was done using SPSS software and CLC Biomedical Genomic 
Workbench (Qiagen, Germany). Normalization and statistical methods were described 
in details in the material and methods of this section. P- value of less than 0.05 was 
considered for significant. 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1. Quality of the Reads and Normalization 
A total of 1.E+09 reads were obtained (average 7.65E+07, STD 3.03E+07). On 
average 92.77% (STD 1.79) of reads were mapped to genes vs 7.23 % (STD 1.79) 
that were mapped to the intergenic region. Over 90% of the reads mapped to mRNA. 
No rRNA was detected, which is due to the depletion step incorporated in the library 
construction. 
The sequencing depth (total reads) between samples varied as illustrated in figure 3. 
Even after the log 10 transformation, the variation persisted showed in figure 3. TMM 
(trimmed mean of M values) normalization, as described in the materials and methods 
section, similar to that in EdgeR, was performed before comparing of samples to 
remove differences in sequencing depth which showed in figure 4. 
Table 4. Distribution of biotypes of RNA-seq reads for 16 samples used in this study 
 
 
 
 
 
 
 
Distribution of Biotypes 
mRNA 90.26% 2.63% 
ncRNA 5.44% 2.57% 
misc_RNA 4.10% 0.54% 
rRNA 0.19% 0.17% 
tRNA 0.00% 0.00% 
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Read Count Normalization across 16 samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Box plot of A) raw reads and B) Log 10 transformed paired reads from 16 
study samples. CNT: Control group (red); CP: Chronic Phase (green); CR: Complete 
Remission (blue). 
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Figure 4. Box plot of TMM normalized paired reads from 16 study samples. CNT: 
Control group (red); CP: Chronic Phase (green); CR: Complete Remission (blue). 
 
4.2. Filtration down and Selection of Transcripts 
These databases were used to identify the expression values and the number of 
transcript variants per gene which generated two types of file including genes 
expression (GE) file which was developed using gene track database, while the 
transcripts expression (TE) file which was created using mRNA track database. For 
this study we used only transcripts expression values. Based on the study objective the 
TE track was selected, which contains a total of 153,438 transcripts for each one of 16 
samples in three clinical phases as CNT: Controls; CP: Chronic Phase; and CR: 
Complete Remission. The expression values were calculated for each biotype such as 
ncRNA, mRNA and miscRNA as described in the materials and methods section. 
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These differentially expressed genes were identified and annotated in each biotype 
category by comparing between each pair of the three clinical phases (CP vs CNT, 
CR vs CNT and CR vs CP). Accordingly, the heatmap, Venn diagram and Principal 
Component Analysis (PCA) were used to illustrate the differentially expressed genes 
in three clinical phases. The initial PCA analysis of 153,438 transcripts failed to show 
any grouping across the 16 samples. To reduce the number of transcripts from 
153,438 the mean differences between each paired group was used to calculate the p 
values. To correct for the number of comparison FDR and Bonferroni values were 
calculated. The initial section was done by filtering away the transcripts that had a p 
value less than 0.05. This reduced the number of transcripts to 136 out which 82 
transcripts were significantly and differentially expressed in CR vs CP and 54 
transcripts in CP vs CNT showed in figure 5.  
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Venn diagram of 136 differentially expressed transcripts in paired comparisons 
 
Figure 5. Venn diagram of 136 significantly differentially expressed transcripts (P< 
0.05) in paired comparisons. (CR vs CP, CP vs CNT, and CR vs CNT) used for 
reducing the 153, 438 transcripts of each of 16 sample to uniquely expressed 136 (82 
+54) transcripts. 
 
To examine if this subset of transcripts can explain the variation between the groups, 
principal component analysis was performed on these 136 transcripts showed in 
figure 6. Using these transcripts 16 samples could be grouped into their clinical 
stages. However, CP2 subject (Chronic phase) was grouped with the control subjects.  
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3D Principal component analysis (PCA) of 136 transcripts  
 
 
 
 
 
 
 
 
 
Figure 6. 3D Principal component analysis (PCA) of 136 transcripts. The first PC 
(PC1), second PC (PC2) and third PC (PC3) explained 26.5, 17.1 and 11.1% of the 
variances, respectively. 
 
To further reduce the number of the transcripts we used two methods. First, we 
clustered them by selecting only those that have a fold change higher than 1.5 Second, 
Euclidean distance between the transcripts was considered. This produced 39 
transcripts that were differentially expressed (P < 0.01 and fold change> 1.5). The 
characteristics of these 39 transcripts are described in table 5 and 6. 
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Table 5. The Description of 39 transcripts selected for this study 
 
 
Transcripts Name Gene name Transcript ID Biotype Status 
ADGRG1_27 ADGRG1 XM_017023892.1 mRNA Predicted  
ANXA3_2 ANXA3 NM_005139.2 mRNA Known 
ATG7_25 ATG7 XM_017005546.1 mRNA Predicted  
BUB1_4 BUB1 NM_004336.4 mRNA Known 
CD53_1 CD53 NM_001040033.1 mRNA Known 
CFLAR_5 CFLAR NR_147253.1 ncRNA Known  
CTC1_1 CTC1 NR_046431.1 ncRNA Known 
CYTH4_1 CYTH4 XR_001755214.1 ncRNA Predicted  
DPY19L3_8 DPY19L3 NM_207325.2 mRNA Known 
FAM208A_7 FAM208A XM_017006030.1 mRNA Predicted  
GATS_1 GATS NR_028040.1 ncRNA Known 
GRAMD1A_6 GRAMD1A XM_011527149.1 mRNA Predicted  
HNRNPA3_4 HNRNPA3 NM_194247.2 mRNA Known 
LUZP1_5 LUZP1 NM_033631.3 mRNA Known 
MAZ_4 MAZ NM_001042539.2 mRNA Known 
MPRIP_7 MPRIP XM_011523766.2 mRNA Predicted  
MYCBP2_13 MYCBP2 XM_017020461.1 mRNA Predicted  
MYCBP2_19 MYCBP2 XM_006719786.2 mRNA Predicted  
MYCBP2_3 MYCBP2 XM_017020459.1 mRNA Predicted  
NFIX_3 NFIX NM_002501.3 mRNA Known 
NLRC5_20 NLRC5 XM_011523376.2 mRNA Predicted  
ORM1_1 ORM1 NM_000607.2 mRNA Known 
PARVG_6 PARVG XM_017028908.1 mRNA Predicted  
PLXNB2_8 PLXNB2 XM_017028704.1 mRNA Predicted  
PLXNB2_9 PLXNB2 XM_005261910.2 mRNA Predicted  
PTPRJ_3 PTPRJ NM_002843.3 mRNA Known 
PXK_20 PXK XM_017006678.1 mRNA Predicted  
RIN3_5 RIN3 NM_024832.4 mRNA Known 
RIT1_3 RIT1 NM_001256821.1 mRNA Known 
SCAPER_6 SCAPER NM_020843 mRNA Known  
SENP5_6 SENP5 XM_011512544.2 mRNA Predicted  
SEPT9_2 SEPT9 NM_001293695.1 mRNA Known 
SLC4A7_3 SLC4A7 NR_135543.1 ncRNA Known 
STAU1_9 STAU1 NM_017453.3 mRNA Known 
TAOK3_4 TAOK3 XM_005253897.1 mRNA Predicted  
TBC1D4_8 TBC1D4 XM_017020883.1 mRNA Predicted  
U2SURP_5 U2SURP NM_001320219.1 mRNA Known 
UTRN_7 UTRN XM_017011245.1 mRNA Predicted  
VNN1_1 VNN1 NM_004666.2 mRNA Known 
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Table 6. The nomenclature of 39 transcripts selected for this study 
Transcripts 
Name 
Transcript ID Database object name 
ADGRG1_27      XM_017023892.1 Adhesion G protein-coupled receptor G1 
ANXA3_2 NM_005139.2 Annexin 
ATG7_25 
XM_017005546.1 ATG7 autophagy related 7 homolog 
(S. cerevisiae), isoform CRA_b 
BUB1_4 NM_004336.4 BUB1 protein 
CD53_1 NM_001040033.1 Leukocyte surface antigen CD53 
CFLAR_5 
NR_147253.1 Homo sapiens CASP8 and FADD like 
apoptosis regulator (CFLAR), transcript 
variant 28 
CTC1_1 NR_046431.1 Conserved telomere capping protein 1 
CYTH4_1 XR_001755214.1 Cytohesin-4 
DPY19L3_8 
NM_207325.2 Probable C-mannosyltransferase 
DPY19L3 
FAM208A_7 XM_017006030.1 Protein FAM208A 
GATS_1 
NR_028040.1 CASTOR family member 3 (CASTOR3), 
transcript variant 4, 
GRAMD1A_6 XM_011527149.1 GRAM domain-containing protein 1A 
HNRNPA3_4 
NM_194247.2 Heterogeneous nuclear ribonucleoprotein 
A3 
LUZP1_5 NM_033631.3 Leucine zipper protein 1 
MAZ_4 NM_001042539.2 Myc-associated zinc finger protein 
MPRIP_7 
XM_011523766.2 Myosin phosphatase Rho-interacting 
protein 
MYCBP2_13 XM_017020461.1 E3 ubiquitin-protein ligase MYCBP2 
MYCBP2_19 XM_006719786.2 E3 ubiquitin-protein ligase MYCBP2 
MYCBP2_3 XM_017020459.1 E3 ubiquitin-protein ligase MYCBP2 
NFIX_3 NM_002501.3 Nuclear factor 1 
NLRC5_20 XM_011523376.2 Protein NLRC5 
ORM1_1 NM_000607.2 Alpha-1-acid glycoprotein 1 
PARVG_6 XM_017028908.1 Parvin, gamma, isoform CRA_b 
PLXNB2_8 XM_017028704.1 Plexin-B2 
PLXNB2_9 XM_005261910.2 Plexin-B2 
PTPRJ_3 NM_002843.3 Protein-tyrosine-phosphatase 
PXK_20 
XM_017006678.1 PX domain-containing protein kinase-like 
protein 
RIN3_5 NM_024832.4 Ras and Rab interactor 3 
RIT1_3 NM_001256821.1 GTP-binding protein Rit1 
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Table 6 Continue. The nomenclature of 39 transcripts selected for this study 
 
 
 
 
 
 
 
 
 
 
 
 
Transcripts 
Name 
Transcript ID Database object name 
SCAPER_6 NM_020843 S phase cyclin A-associated protein in the 
endoplasmic reticulum 
 
SENP5_6 XM_011512544.2 SUMO1/sentrin specific peptidase 5, 
isoform CRA_a 
SEPT9_2 NM_001293695.1 Septin 9, isoform CRA_b 
SLC4A7_3 NR_135543.1 Anion exchange protein 
STAU1_9 NM_017453.3 Double-stranded RNA-binding protein 
Staufen homolog 1 
TAOK3_4 XM_005253897.1 Serine/threonine-protein kinase TAO3 
TBC1D4_8 XM_017020883.1 TBC1 domain family member 4 
U2SURP_5 NM_001320219.1 U2 snRNP-associated SURP motif-
containing protein 
UTRN_7 XM_017011245.1 Utrophin 
VNN1_1 NM_004666.2 Pantetheinase 
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Out of 39 transcripts, 34 are mRNA and 5 are ncRNA. Those with reference number 
starting with letter X are predicted and unknown. The heatmap of 39 transcripts shows 
a cluster of the transcripts that are differentially expressed (up-regulated (green) and 
down-regulated (red)) in one or two of three different groups showed in figure 7. 
Heatmap of 39 differentially expressed transcripts clustered in three different groups 
of CNT: Control group, CP: Chronic Phase, and CR: Complete Remission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Heatmap created from Log10 transformed CPM of 16 Samples and 39 
transcripts were simultaneously clustered using complete linkage. Each column 
corresponds to one sample, and each row corresponds to log CPM per transcript. The 
numbers in front of each transcript are the splice variants. Euclidean distance was 
used to measure the ordinary distance between two points. Data were further filtered 
by setting the minimum absolute fold change to 1.5 and FDR p value to less than 0.01  
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Further filtration was performed by using the Venn diagram to reduce the number of 
39 transcripts to 23 significantly expressed transcripts in paired groups by considering 
the more stringent FDR p value of less than 0.0001 and the fold change cut off for 
each transcript at 1.5 illustrated in figure 8. Transcripts with expression value less 
than 10 were excluded to minimize the false positive reads. 
After applying the FDR p value <0.0001, the majority of the resulted genes 
(transcripts) are protein coding except the four transcripts such as CFLAR_5, 
GATS_1, SLC4A7_3, and CTC1_1 are LncRNA.  
Venn diagram of 23 significantly expressed transcripts in paired groups comparison 
CR vs CP, CP vs CNT, and CR vs CNT. 
 
 
 
 
 
 
 
Figure 8. Venn diagram created for paired groups based on the fold change cut off of 
1.5 for raw count per transcript. 136 transcripts were reduced to 39 by filtering FDR 
p value lower than 0.01 CNT: Controls; CP: Chronic Phase; CR: Complete 
Remission. 23 transcripts that are marked in red are those that were filtered by using 
a more stringent FDR  of less than 0.0001 
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4.2.1. Transcripts that are differentially expressed in patients in chronic phase    
compared to healthy individuals 
 
 
 
 
 
 
 
Figure 9. Volcano plot showing transcripts selected from Venn diagram created for 
paired groups based on the fold change cut off of 1.5 and FDR of less than 0.0001 
CNT: Controls; CP: Chronic Phase; CR: Complete Remission. 
 
As shown in figure 9. There are 17 transcripts that are differentially expressed in the 
subjects with chronic phase. We selected eight of these transcripts by setting the cut 
off of FDR value to less than 0.0001: MAZ_4, RIT1_3, BUB1_4, CFLAR_5, 
PARVG_6, SENP5_6, GATS_1, TAOK3_4 All except MAZ_4, RIT1_3 and TAOK3_4 
are highly expressed in the chronic phase compared to control subjects. 
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MAZ_ 4 or Myc-associated zinc finger protein. It was strongly down regulated in the 
CP subjects compared to the control group in which it is significantly upregulated 
with an increased fold of 200 it has been shown to be involved in cellular nitrogen 
compound metabolic process.  
It resides in cytoplasm, nucleoplasm and nucleus and has been reported to have DNA 
and RNA binding (Bossone, Asselin, Patel, & Marcu, 1992; Robinson & Oshlack, 
2010) (Baltz et al., 2012), ion binding (Song et al., 2001) and nucleic acid binding 
transcription factor activity (Baltz et al., 2012; Castello et al., 2012) Because of these 
central roles in the cellular function it conceivable to imagine that some of the above 
activity in the blood cells are suppressed. 
RIT1_3 is a GTP-binding protein and is also known as RIBB, RIT and ROC1. RIT1 
encoding a member of RAS family proteins. It is a part of cellular component and 
plasma membrane and is involved in ion binding as participating in neuron stress-
mediated survival and signal transduction such as RAS/MAPK pathway (Aoki et al., 
2013) ("RIT1 gene Ras like without CAAX 1," 2018) A study conducted by Segui, G., 
et al, 2013 reported that 10% to 50% of somatic mutation in RAS subfamily genes 
particularly RIT1 gene occurred in myeloid neoplasms including MPNs, mixed 
myelodysplastic MDS and chronic myelomonocytic leukemia CMML. Also it has 
been found that 15% to 30% of acute myeloid leukemia cases have somatic mutations 
in RAS family genes (Gomez-Segui et al., 2013) 2% of the cases with lung 
adenocarcinoma have somatic mutations in RIT1. Therefore, RIT1 could be 
considering as an oncogenic gene (Berger et al., 2014) However, In this particular 
study, the gene is upregulated in the healthy subjects, who did not have any condition 
related to chronic myeloid leukemia with an increased expression value of 600 fold 
compared to chronic phase. 
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TAOK3_4 or Serine/threonine-protein kinase TAO3 is involved in DNA metabolic 
process, cell cycle response to stress, signal transduction and cellular protein 
modification process .This gene expressed in mitochondria as serine/threonine protein 
kinase, it activates the p38/MAPK14 stress-activated MAPK cascade but inhibits the 
basal activity of the MAPK8/JNK cascade (W. Zhang et al., 2000) (Raman, Earnest, 
Zhang, Zhao, & Cobb, 2007). The encoded protein is a member of the GCK subfamily 
of STE20-like kinases. TAOK3 gene is ubiquitous expressed in the brain and prostate 
tissues with RPKM values of 12 and 9.7 respectively ("Gene ID: 51347 TAOK3 TAO 
kinase 3 [ Homo sapiens (human) ]," 2018) In the present research, the 
downregulation of the gene in cancers and subsequent upregulation in health 
individuals with an increased expression value of 600 fold suggest that the gene is a 
tumor suppressor. 
The downregulation of MAZ, RIT1, and TAOK3 genes in chronic phase patients might 
be an indication of aberrant functions that is required for normal function of blood 
cells and be a good diagnostic and monitoring tool for those in the chronic phase.  
Interestingly, the subjects in the chronic phase were the only one with highly 
upregulated BUB1_4, CFLAR_5, PARVG_6, SENP5_6 and GATS_1 transcripts. 
BUB1_4 is known as budding uninhibited by benzimidazoles encodes a 
serine/threonine- kinase protein, which acts in phosphorylation of the mitotic 
checkpoint particularly, the activation of the spindle assembly checkpoint (SAC) 
("Gene ID: 699  BUB1 mitotic checkpoint serine/threonine kinase [ Homo sapiens 
(human) ]," 2018) On the other hand, this gene has a role in inhibiting the activity of 
anaphase complex/cyclosome during the mitotic division, DNA repair and 
chromosomal stability, which is one of the roles of tumor suppressor. Therefore, any 
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mutations in this gene lead to various cancers and aneuploidy. This gene is abundant 
in testis and lymph node tissues with RPKM values of 25.2 and 11.3 respectively. In 
this study, the gene showed an irregular pattern of upregulation in the chronic phase 
with an expression level of 6500 fold compared to healthy individuals. In a study 
conducted by Hatfield, Reikvam, and Bruserud (2014), stated that seven of 31 patients 
with acute myeloid leukemia AML had a long-term malignant cell proliferation in 
vitro showed an altered expression of BUB1 and other cell cycle regulator genes 
(HMMR, NUSAP1, AURKB, CCNF and DLGAP5), which was suggested to be used 
as a potential therapeutic target of AML (Hatfield, Reikvam, & Bruserud, 2014) 
Another study revealed BUB1 to be one of the targets of miR-155, which acts as its 
negative regulator. Oncogenic miR-155 was found to be overexpressed in multiple 
solid and hematological malignancies including breast, lung, colon and leukemia 
leading to genomic instability by causing defects in DNA mismatch repair, telomere 
integrity and chromosome stability through binding to 3’-UTR of BUB1 gene causing 
the depression of BUB1 protein levels to (–70%) in normal human dermal fibroblast 
(HDF) cells injected with lentiviral vector carrying miR-155 and to (–30%) in breast 
cancer cell line (MCF7) followed by a decreased to (–50%) detected in HCT116 cells 
using western blot test after ectopic expression of miR-155 to these cells (Pagotto et 
al., 2018) This is a surprised finding as it is over expression in the chronic phase and 
to some extent but not significantly up regulated in the complete remission, compared 
to controls, points to opposite function of BUB1 as being oncogenic.  
PARVG_6. Parvin, gamma, isoform CRA_b is highly expressed in bone marrow, 
spleen and lymph nodes. It has been shown to be involved in cell adhesion, 
cytoskeleton organization and fibroblast migration (Korenbaum, Olski, & Noegel, 
2001; Yoshimi et al., 2006) In this research, PARVG expression was 280 fold 
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increased in the chronic phase patients compared to control group. It was also 
elevated in the complete remission phase but was not significant. Given the fact that it 
is involved in the interaction of leukocytes with the vascular endothelium it might be 
of great interest to explore the susceptibility of the CML patient to infection.  
SENP5_6 Also known as SUMO-specific peptidase 5, functions in a reversible 
posttranslational modification. It has two main functions in the SUMO pathways 
which are important in regulating cellular mechanisms such as the cell division and 
the transcription process by catalyzing the cleavage of SUMO1 from a number of 
mitochondrial substrates, therefore, overexpression of cytosolic SENP5 gene 
contribute in regulating the SUMO1 proteolysis from the mitoconderial substrates 
which affecting the morphology and metabolism of mitochondria (Zunino, Schauss, 
Rippstein, Andrade-Navarro, & McBride, 2007) Another pathway of SENP5 gene is 
the de-conjugation of SUMO2 and SUMO3 from their targeted proteins Unlike 
ubiquitination, SUMOylation does not guide the protein for degradation. It has been 
shown to play a role in promoting the tumor progression. However both SUMO and 
ubiquitin proteins are directed by enzymatic cascade. SENP5 is a SUMO-specific 
protease that generates the precursors of SUMO-proteins. It also acts to remove the 
SUMO proteins from SUMO conjugated substrates; a process known as isopeptidase. 
However, SENP5 would be unable to process the ubiquitin proteins. It has been 
shown to have a prognostic potential for esophageal carcinoma and ovarian serous 
cystadecarcinoma. SENP5 is expressed in testis and brain tissues with RPKM values 
of 8.4 and 6.3 respectively ("Gene ID: 205564 SUMO specific peptidase 5 [ Homo 
sapiens (human) ]," 2018) A study revealed that SENP5 gene is one of the seven 
oncogenes that are highly expressed in different tumors. Tumor Genome Cancer Atlas 
(TCGA) cells which reached to 20% in esophageal carcinoma and lung squamous cell 
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carcinoma. Also in ovarian serous cystadenocarcinoma samples, the frequency of 
genetic alteration such as, gene copy number gains (CNG) for SENP5 was 22% 
Moreover, the highest expression level of SENP5 gene correlated with poor prognosis 
of breast cancer, while the low expression level of this gene in breast cancer 
associated with good prognosis (Wee, Liu, Lu, Li, & Zhao, 2018) Another study 
emphasized the role of SENP5 in promoting the growth of tumor cells. It was reported 
that SENP5 is highly expressed in hepatocellular carcinoma (HCC), about 3.3 fold 
change compared to adjacent normal tissues. Also it was detected that SENP5 
regulates the response to DNA damage through deSUMOylation of ATRIP; known as 
ATR-interacting protein kinase that regulates the response to DNA damage 
checkpoint pathway, thus SENP5 could be a promising therapeutic target of HCC (Jin, 
Pei, Xu, Yu, & Deng, 2016) This study showed a 264 fold expression of SENP5 gene 
in the chronic phase group compared to that in complete remission group. SENP5 
could therefore, potentially, be used as a biomarker for chronic phase of CML. 
CFLAR_5 (CASP 8 and FADD like apoptosis regulator) and GATS_1 (transcript 
variant 4 of CASTOR family member 3 (CASTOR3) are both LncRNAs. The former 
transcript characterized by having some transcript variants containing different 
isoforms, Therefore CFLAR gene is clinically significance with 17 pathogenic 
variances. CFLAR transcript is abundant in fat tissues, bone marrow and lung tissues 
with RPKM values of 11.3, 9.5 and 9.4 respectively. The latter is a favorable 
prognostic marker in cervical cancer. This variant of GATS-1 is generated due to a 3' 
UTR alternative splice pattern compared to the variant 1. It is non-coding because of 
its 5'- translational start codon tags it for the nonsense-mediated mRNA decay (NMD) 
pathway. Not much is known about this LncRNA. However, the results obtained from 
our study shows a 165 fold significant increase for both LncRNAs in the subjects with 
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chronic phase compared to healthy individuals. This result could help the physicians 
in diagnosing the leukemia cells in the early stages. Although they are also elevated in 
the complete remission subjects but it is not significant. A further study may shed a 
light on the significance of these two LncRNAs as a biomarker. 
4.2.2. Transcripts that are differentially expressed in complete remission only 
compared to chronic phase 
 
 
 
 
 
 
 
 
Figure 10. Volcano plot showing transcripts selected from Venn diagram created for 
paired groups based on the fold-change cut off of 1.5 and FDR of less than 0.0001 
CNT: Controls; CP: Chronic Phase; CR: Complete Remission. 
 
Figure 10. 10 transcripts found in this study that have a significant expression in the 
subjects of the complete remission only. We selected five of these transcripts by 
setting the cut off of FDR value to less than 0.0001: TBC1D4_8 HNRNPA3_4 
SLC4A7_3 GRAMD1A_6 CTC1_1 
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HNRNPA3_4 encodes for heterogeneous nucleus ribonuleuprotein A3, this protein is 
one of (hnRNPs) isoforms that includes hnRNPA0, A1, A2, and B1. They play a 
significant role in regulating different cellular processes and are involved in nucleic 
acid breakdown. This protein is a nucleic acid binding protein mediated in trafficking 
of RNA molecules in cytoplasm through binding to RNAs that contain cis-acting 
regulatory element known as A2RE. It might have a role in splicing process of the 
pre-mRNA. This gene is highly abundance in appendix and lymph node with RPMK 
value of 56.8 and 56 respectively. It has been shown to have a pathogenic variance. 
Takoya identified 25 proteins that were differentially expressed in Cisplatin- naïve 
and Cisplatin-resistance bladder cancer cell lines (T24 and T24CDDPR, respectively) 
HNRNPA3, PGK1, TK and SERPINB2 proteins had an increased expression pattern of 
more than 1.5 times in T24CDDPR compared to that observed in T24. HNRNPA3 and 
PGK1 were the most highly expressed proteins in the bladder cancer cells regardless 
of the concentration of the Cisplatin drug used (Taoka et al., 2015) Garcia and 
Gonzalez showed that transcript level of HNRNPA3 gene in lung cancer cell lines, 
under different stress conditions such as hypoxia, serum deprivation was the lowest 
compared to the highest transcript level of HNRNPA2, B1, A0 & A1 (Romero-Garcia, 
Prado-Garcia, & Lopez-Gonzalez, 2014) In this study, the expression of HNRNPA3 
was significantly up regulated in subjects with complete remission of CML with a 
significant increase in expression level of 2200 fold compared to control and chronic 
phase subjects. However, given the fact that one of the control subject (CNT 1) had a 
comparable expression of HNRNPA3, it is more likely that HNRNPA3 is 
downregulated in the chronic phase patients than over expression in the complete 
remission. If that would be the case then HNRNPA3 can be used as diagnostic tool for 
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the monitoring the recovery of those that in the complete remission and maybe 
identify those that are at risk of relapse. 
SLC4A7_3. Is the transcript variant number 12 of solute carrier family 4 member 7 
and is a LncRNA. This locus encodes a gene for the transmembrane protein of sodium 
bicarbonate co-transporter. The encoded protein carry both sodium and bicarbonate 
ions and thus this gene is considered as an electroneutral co-transporter and regulates 
the intracellular PH necessary in transmission of vision and auditory sensors. In this 
study this LncRNA was highly expressed with the fold value of 290 in the subjects of 
the complete remission phase .However, just like the case of HNRNPA3 it is more 
likely that the expression is suppressed in the CP since one subject in the control 
groups had expression as well. This might be a good marker, along HNRNPA3 for the 
monitoring of CR group. 
TBC1D4_8 known as Rab-GTPase-activating protein, acts in the downstream 
signaling pathway and is characterized by having several binding domains such as 
Rab-GTPase, two types of phosphotyrosine (PTB1 and PTB2), calmodulin domain 
CBD and , multiple AKT phosphormotifs , where the phosphorylation of this gene 
takes place. It is a member 4 of TBC1 family and is believed to have a role in glucose 
homeostasis, through controlling the transportation of glucose transporter 4 (GLUT4), 
activated in the presence of insulin and carry out the glucose into the fat and 
musculoskeletal tissues where the glucose will be stored as glycogen and used it for 
producing energy after the glucose oxidization. It has been shown that low expression 
of TBC1D4 gene resulted in accumulation of GLUT4 level at cellular plasma 
membrane indicating that this gene has a crucial role in saving the GLUT4 level in 
cells. The phosphorylation of the protein domain binding to the TBC1D4 gene causes 
this gene to be separated from the glucose transporter vesicles hence these vesicles 
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will move toward the cell surface. Any structural aberrations in TBC1D4 gene would 
lead to manifestation of Type2 diabetes. TBC1D4 gene is highly expressed in adrenal 
and ovary with the RPKM values of 28.911 and 15.25 respectively. Clinically, this 
gene could be either benign or pathogenic since it has 45 pathogenic variances. 
("Gene ID: 9882 TBC1D4 TBC1 domain family member 4 [ Homo sapiens (human) 
]," 2018) It is implicated in prostate cancer progression and cell growth. Increased 
level of androgen receptor AR would increase the glucose uptake via translocating the 
glucose transporter GLUT12 to the plasma membrane. Consequently, this would 
increase the expression of TBC1D4 gene, the regulator of the glucose transport. This 
abnormal signaling pathway of metabolism is one of the hallmarks of cancer (White 
et al., 2018) Another study shows that silencing of AKT substrate for TBC1D4 gene 
would reduce the fibroblast and cancer cells proliferation and promote the cell cycle 
arrest in different cell types. Particularly, mediated by upregulation of cyclin-
dependent kinase inhibitor at G1/S phase (P21) However P21 down regulation 
correlated with AS160 overexpression which in turn will save the arrested cell and the 
reduced level of AS160 in cells It has been known that phosphorylated AS160 at T-642 
residue (P-AS160) correlated with increased cellular proliferation markers and the 
tumor size since this gene is highly expressed in breast cancer tissues compared to 
normal one (Gongpan, Lu, Wang, Xu, & Xiong, 2016) Our study shows that TBC1D4 
gene has high expression level of 2200 fold in complete remission. This observation 
will follow the same argument made for HNRNPA3_4 and SLC4A7_3, that it might be 
a downregulation in the CP subjects than anything else.  
CTC1_1 is the transcript variant number 2 for CST telomere replication complex 
component 1 (CTC1) and is lncRNA. CTC1 forms a heterodimer with STN1, which 
causes the formation of alpha enzyme involved in DNA replication. CTC1 gene is 
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known to maintain the telomere structure from degradation. Different pathological 
conditions occur as a result of the variation of this gene. These conditions including, 
Cerebroretinal microangiopathy represented by the calcifications and cyst, 
dyskeratosis congenital also the ductal breast carcinoma ("Gene ID: 80169  CTC1 
CST telomere replication complex component 1 [ Homo sapiens (human) ]," 2018) 
Walsh M. K. et al. (2016) discovered eight genes that were related to the leukocyte 
telomere length (LTL) polymorphisms. These genes were ACYP2, TERC, NAF1, 
TERT, OBFC1, CTC1, ZNF208 and RTEL1. They found that the genetic variations 
associated with longer telomere length were implicated in increased risks of 
melanoma, glioma and lung cancer in adult, whereas, in children and adolescent, aged 
12 to 19, it increase their risk of the neuroblastoma. It was observed that the leukemic 
cells in children were caused by a mutation in ACD gene, which normally acts to 
telomere protection (Walsh et al., 2016) we observed an expression of lncRNA of 
CTC1_1 in CR group with 65 fold compared to CP. Although this gene was not 
significant it was also expressed in the control group and completely absent in the CP 
group.  
GRAMD1A_6 is a predicted transcript variant (X1) of GRAM domain containing 1A 
(GRAMD1A) It is a paralog of GRAMD1B gene. It is highly expressed in lung and 
spleen tissues with the RPKM value of 13.7 and 13.3 respectively. It has seven 
pathogenic variances, one of which is pathogenic associated with ductal breast 
carcinoma. There is a limited amount of information about this gene and its role in 
leukemia especially in CML. However, our data shows high expression count of 260 
fold in CR subjects followed by one control subjects. The absence of expression of 
this transcript variance in the CP group, in combination with other above mentioned 4 
transcripts, might be used as diagnostic marker. Fu et al. (2016) examined the role of 
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GRAMD1A in the development and progression of Hepatocellular Cellular Carcinoma 
(HCC) by analyzing the association between the clinical conditions of 78 patients. 
They included in their study those with advanced stages of HCC (stage III to IV) 
Furthermore, they considered in their study the link between the survival time and the 
expression of GRAMD1A, using the log-rank test and they detected that patients with 
elevated levels of GEAMD1A gene had a poor prognosis. In addition to these, Fu et al. 
(2016) studied the relation between the GRAMD1A levels and the tumor relapse and 
growth. They found that HCC stem cells markers such as CD133 and CD90 were 
positively correlated with GRAMD1A overexpression which indicates the role of 
GRAMD1A gene in promoting the self-renewal process of HCC stem cells. Up 
regulated levels of GRAMD1A gene are positively concomitant with HCC tumor 
expansion and chemo-resistance. This is determined by measuring the apoptotic 
markers represented by PARP and pro-caspase, which are cleaved by GEAMD1A 
overexpression and simultaneous increases the anti-apoptotic protein, BCL-X (Fu et 
al., 2016) Although GRAMD1A is considered as a prognostic marker for HCC, it can 
be used as a potential therapeutic target and an indicator for the treatment 
improvement of psoriasis. The upregulation of GRAMD1A gene correlated with 
effective treatment of skin psoriasis plaques using narrow band-Ultraviolet B 
radiation (NB-UVB) concurrently with imiquimod (IMQ) ; Toll-Like receptor 7 
(TLR7) agonist (Tacastacas et al., 2017). 
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4.2.3. Transcripts that are differentially expressed in paired comparisons 
between chronic phase vs complete remission and healthy subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Volcano plot showing transcripts selected from Venn diagram created for 
paired groups based on the fold change cut off of 1.5 and FDR of less than 0.0001 
CNT: Controls; CP: Chronic Phase; CR: Complete Remission. Log2 fold changes are 
shown for 5 genes in two group comparisons: A) Chronic Phase vs Controls and B) 
Complete Remission vs Chronic Phase. 
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In Figure 11.There are three transcripts that are differentially upregulated with 
significant pattern in the subjects with chronic phase only these are U2SURP_5, 
SEPT9_2, and DPY19L3_8 while two of which including CYTH4_1 and PLXNB2_8 
were significantly upregulated in complete remission subjects and in healthy 
individuals compared to chronic phase by setting the cut off of FDR value to less than 
0.0001 
U2SURP_5 Is a transcript variant number 2 of U2 snRNP associated SURP domain 
containing (U2SURP), and a predicted to encode intracellular protein.  
The gene is highly expressed in chronic phase of CML only. U2SURP is considered 
as a prognostic marker in many cancers and its expression is associated with favorable 
or unfavorable depending on the type of cancer. It is among the genes that have been 
identified via molecular cloning that includes those encoding spliceosomal proteins 
novel RNA helicases and protein isomerases and GTPases (Will & Luhrmann, 1997) 
Part of the 17 S U2SnRNP is Human Splicing Factor (SF3a) that interacts with the 
pre-mRNA branch site during the formation of the spliceosome. According to Kramer 
et al, subunits of 60, 66 and 120 kDa are required for the in Vitro formation for SF3a 
RNA interference with the process formation of the subunits from HeLa cells inhibits 
the splicing process. Once splicing is inhibited, especially during the chronic phase of 
the CML, it results in the up regulation of the U2SURP gene. Thus, SF3a is a 
constitutive splicing factor (Kramer et al., 2005). 
Around 70% of the human genes have shown to have alternative splice forms. 
U2SURP gene introduces spliceosomal errors that would result in the formation of 
aberrant transcripts, not found in normal cells. Instead, they are indicative of the 
intrinsic property of the cancer cells. Among the cellular alterations include a change 
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in splice site selection in cancer cells subsequently, affecting the genes implicated in 
tumor progression and in cancer susceptibility. The splicing defects caused by the 
U2SURP gene can arise from either inherited or somatic mutations in the cis-acting 
regulatory elements can include branch sites, splice donor, intronic and exonic 
splicing silencers and enhancers. Other changes include concentration, variations in 
composition, altered activity of the regulatory proteins and localization (Kalnina, 
Zayakin, Silina, & Line, 2005) In this case, up regulation of the U2SURP gene, a 
splice variant during the chronic phase of CML results in failure in correct recognition 
of splice sites hence the cancer-specific splice forms. Therefore, the identification of 
the U2SURP gene as a cancer-specific splice form is important as diagnostic and 
prognostic biomarkers in CML. In this case, the significant up regulation of the 
U2SURP_5 splice variant, a cancer-specific splice form during the chronic phase of 
CML with a significant increase in fold value of 2100 which may interfere with the 
detection of wild type transcript.  
No current studies have exploited the influence of U2SURP gene on CML patients. 
However, the results obtained in the research can provide a background for future 
investigation on the possibility of the gene expression reducing progression of 
leukemic cells.  
SEPT9_2 Is a transcript variant number 8 for a gene that encodes GTP-binding 
protein. This gene is a member of the septin proteins family characterized with 
GTPases activity and are associated with cellular cytoskeleton, such as actin and 
microtubules. This gene plays a role in cellular process such as cytokinesis, motility, 
polarity as well as controlling the cell cycle. SEPT9 gene is equally abundant in 
spleen and lymph node tissues with RPKM value of 19.8 Mutant SEPT9 gene has 
been implicated in certain pathogenic conditions such as hereditary neuralgic 
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amyotrophy (HNA) and rare genetic disease such as muscular atrophy ("Gene ID: 
10801 SEPT9 septin 9 [ Homo sapiens (human) ]," 2018) SEPT9 gene is implicated in 
acute myelomonocytic leukemia when translocated with mixed lineage Leukemia 
(MLL) gene that located on chromosome 11. SEPT9 is one of the MLL fusion proteins 
that partners septins, nuclear and cytoplasmic proteins, and histone 
acetyletransferases. Furthermore, SEPT2, SEPT5, SEPT6, and SEPT11 are engaged 
with MLL chromosomal rearrangement. Most of MLL-SEPTIN genes fusions are 
identified in hematological malignancies (Cerveira, Bizarro, & Teixeira, 2011) ABL1 
gene rearrangements have been implicated in several leukemia especially in chronic 
myeloid leukemia, other types of leukemia such as T- or B-lymphoblastic leukemia 
and a rare type of peripheral T-cell prolymorphocytic leukemia (T-PLL) T-PLL is 
resulted by SEPT9-ABL1 fusion gene, a novel fusion gene discovered by Suzuki et al., 
2014 who identified the resistance of this fusion gene to tyrosine kinase inhibitors 
(TKIs) (Suzuki et al., 2014) According to the function of septin proteins in 
cytokinesis and controlling the cell cycle, it has been assumed that SEPT9 gene could 
be a candidate suppressor genes in ovarian cancer. However, SEPT9 gene is 
significantly upregulated in chronic phase of CML and the highly expression patterns 
of this gene is recognized in almost all chronic phase samples with 2100 fold and 
those patients that were resistance to tyrosine kinase inhibitors (TKIs) compared to 
healthy individuals and the subjects in complete remission. 
DPY19L3_8 Similar to U2SURP, DPY19L3 is a prognostic marker. This transcript is 
variant number 1 for the dpy-19 like C-mannosyltransferase 3 (DPY19L3) gene. In 
this study this transcript is highly upregulated in the chronic phase of CML only and 
the fold value of this gene was 270. DPY19L3 has eight pathogenic variances, four of 
them with uncertain significance. Niwa, Suzuki, Dohmae, and Simizu (2016) suggest 
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that C-mannosylation is a rare type of glycosylation that is critical in regulating 
secretion, protein-protein interaction as well as enzymatic activity. Furthermore, this 
study shows that DPY19 is a C-mannosyltransferase in Caenorhabditis elegans. In 
experiments involving gain and loss of functions, DPY19L3 modifies Rspo1 at W 
(156) on the basis of the spectrometry. Apart from chronic CML, the gene is 
expressed in certain human tumor cell lines which is an indication of its malignant 
roles in tumorigenesis (Morishita, Suzuki, Niwa, Dohmae, & Simizu, 2017) 
CYTH4_1 Is a transcript variant number (X2) of gene encoding Cytohesin-4 protein, a 
member of cytohesin family known as PSCD family. Proteins in the PSCD family 
consist of three domains: N-terminal coiled-coil motif, central Sec7 domain, which 
contains the activity of guanine- (nucleotide) exchange protein GEP, and C-terminal 
pleckstrin homology (PH) domain, which interacts with the phospholipids in cellular 
membrane. This gene acts on ADP-ribosylation factors (AFRs) activity through 
activation of guanine nucleotide-binding proteins participated in proteins sorting and 
vesicular trafficking pathways ("Gene ID: 27128 CYTH4 cytohesin 4 [ Homo sapiens 
(human) ]," 2018) This gene is expressed ubiquitously in appendix and spleen tissues 
with RPKM values of 28 and 22.5 respectively. In this study, this transcript variants 
was highly downregulated in the CP group compared to both complete remission and 
control groups with a significant high expression value of 270 fold in both subjects. 
PLXNB2_8 Is a transcript variant number (X6) of gene encoding plexin B2, It is a 
member of class B of plexin 2 family. This gene is a membrane receptor protein 
involved in cell migration and in axonal growth guidance processes responding to 
semaphorins. Semaphorins are a large family of proteins that were identified as 
axonal growth factors and have a role in developing the central nervous system 
(CNS).  
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PLXNB2 gene is highly expressed in renal tissue with RPKM value of 34.56 clinically 
this gene tends to be pathogenic ("Gene ID: 23654 PLXNB2 plexin B2 [Homo 
sapiens (human)] 
", 2018) PLXNB2 is one of the target genes for miR-126-3p and is found to be 
implicated in cancer pathways. It activates RhoA/ROCK signaling pathway, which 
plays a role in cell proliferation and transformation in esophageal squamous cell 
carcinoma (ESCC) and in breast cancer. Therefore, miR-126 can inhibit the 
proliferation of cancer cells by targeting PLXNB2 and decreases the expression of this 
gene. The downregulation of PLXNB2 in turn inhibits the RhoA/ROCK signalling 
pathway. This finding was observed in colon cancer, while downregulated miR-126-
3p lead to increased expression of PLXNB2 followed by increased the proliferation 
and the severity of tumor cells, this pathogenic situation occur in lung 
adenocarcinoma (Q. Chen et al., 2016) In this study, this transcript variants was 
highly downregulated in the chronic phase subjects compared to both complete 
remission and control groups with a highly significant fold value of 1100 in complete 
remission but this gene has low significant in healthy individuals with a fold value of 
130. 
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4.2.4. Transcripts that are differentially expressed in both chronic phase and 
complete remission vs healthy subjects. 
 
 
 
 
 
 
 
 
Figure 12. Volcano plot showing transcripts selected from Venn diagram created for 
paired groups based on the fold change cut off of 1.5 and FDR of less than 0.0001 
CNT: Controls; CP: Chronic Phase; CR: Complete Remission. Log2 fold changes are 
shown for 5 genes in two group comparisons: A) Chronic Phase vs Controls and B) 
Complete Remission vs Controls. 
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Figure 12.Illustrated seven differentially expressed transcripts in chronic phase and 
complete remission compared to control group by setting the cut off of FDR value to 
less than 0.0001, there are only four transcripts which significantly overlapped 
between chronic phase and complete remission including: LUZP1_5, PXK_20, 
UTRN_7, and SCAPER_6 while PTPRJ_3 is the only transcript showed a stringent 
fold value with extreme significant in healthy individuals. 
LUZP1_5 Is the transcript variant number 1 of gene that encodes for Leucine zipper 
protein 1. There are certain motif-containing protein, in which their lower expression 
has been associated with disease progression in cancer. LUZP is mostly expressed in 
adult’s brain, and in both the small intestine and the duodenum, with RPKM value of 
10.5 and 8.9 respectively. Deficiency in LUZP protein causes a defect in neural tube 
closure in mice during the brain development ("Gene ID: 7798 LUZP1 leucine zipper 
protein 1 [ Homo sapiens (human) ]," 2018). Guangbang, Li, and Deiji (2016) pointed 
out that the protein encoded by LUZP gene plays an important role in the 
developmental stages. Aberrant expression or mutation of this gene could lead to 
cancer. Its overexpressed pattern has been shown to be correlated with different solid 
tumors including breast, cervical, kidney and pancreas. Elevated level of LUZP 
mRNA has been reported in Hepatocellular carcinoma (HCC) samples compared to 
normal liver tissues (1. 87 ± 0. 11 vs 0.58 ± 0.05, P < 0.01) The differences of the 
gene expression between these two groups were measured based on the Tumor 
Lymph Node metastasis (TNM) stage, disease recurrence and the portal vein invasion. 
Therefore, the high expression of LUZP gene in HCC tissues correlated with the 
patient’s poor prognosis (G. Li, Yuan, Liu, & Liu, 2016).  
Viphakone et al., (2015) shows that cancer testis antigens (CTAs), known as Luzp4, 
binds to mRNA export receptor of other genes and stimulates their activity.  
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This class of LUZP protein is upregulated in several tumors particularly in melanoma 
(Viphakone et al., 2015). Interestingly, in our study population, LUZP_1 is 
significantly expressed in both complete remission and chronic phase of chronic 
myeloid leukemia (CML) subjects with high fold of 1100 in both groups of CML. 
PXK_20 Is the transcript variant X2 of mRNA, predicted to code a phox (PX) domain 
containing serine/threonine kinase like (PXK) protein which involved in synaptic 
transmission. Furthermore, the gene is involved in the degradation of epidermal 
growth factors. The variations in the regulation of PXK gene are associated with 
susceptibility to systemic lupus erythromatosus. In addition, alternative splicing leads 
to multiple transcript variants. This gene binds to and modulates brain Na, K-ATPase 
subunits ATP1b1 and ATP1b3. Not much is known about PXK gene. However, in our 
study this variant of PXK is significantly expressed in both complete remission and 
chronic phase of chronic myeloid leukemia (CML) subjects with an increased fold of 
1100 in chronic phase compared to complete remission with 800 fold, In terms of 
significant expression, PXK gene has a distinct significant value in chronic phase 
compared to that in complete remission. 
UTRN_7 Is the transcript variant X2 of mRNA, predicted to code utrophin (UTRN) 
protein. It was annotated using gene prediction methods. UTRN is a member of DMD 
gene that encodes a rod-shaped protein known as Utrophin or Dystrophin like protein 
(DMDL) It is the large muscular protein that is located at neuromuscular synapse and 
myotendinous junctions. It is similar in structure and functions to Dystrophin gene 
(DMD) and considered as an alternative to Dystrophin gene. It has a role in 
supporting the cytoskeleton of the muscle fibres and links them to extracellular matrix 
proteins. Utrophine can be used as drug to make up the lack of endogenous protein 
expression of Utrophin that result in Duchenne/Becker muscular dystrophy. The 
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UTRN gene is highly expressed in thyroid and fat tissues with an RPKM value of 15.3 
and 15.0 respectively, in fetal tissues such as placenta, heart and intestine. UTRN is a 
pathogenic gene with nine pathogenic variances. In Meta-analysis study conducted by 
Wang X. Y. et al., 2013, they used a total of 1174 gene expression data from two 
studies that were collected from advanced stages of the prostate cancer. They found 
eight genes to be differentially expressed and related to the progression of the prostate 
cancer (NBL1, C10orf116, SMTN, PARM1, UTRN, SYNPO2, MYLK and PTN) (X. Y. 
Wang et al., 2013) under hypoxia conditions CLK1 and CLK3 are regulators of the 
alternative splicing process. A study identified that UTRN gene to be one of the 12-
cancer associated genes that showed a significant increase in CLK1 and CLK3 
expression in prostate cancer cells (PC3). The elevated levels of CLK3 expression 
were detected in different hypoxic cancer cell lines such as colon HT29, breast cancer 
MCF7 and prostate DU145 (Bowler et al., 2018) It was found that both UTRN gene 
and SXT11 gene were involved in the pathophysiology of peripheral T-cell 
Lymphoma (PTCL) and therefore considered as a tumor suppressor gene of (PTCL) 
but not in other lymphomas such as NK-cell lymphoma and diffuse large B-cell 
lymphoma (DLBCL) (Yoshida et al., 2015) Another study reported that UTRN gene is 
a candidate tumor suppressor gene, which is downregulated in some primary tumors 
compared to normal tissues. Any mutation in UTRN mainly deletion has been 
associated with tumor cell growth and tumor progression (Y. Li et al., 2007) our 
findings showed that this variant of UTRN is significantly expressed in both complete 
remission and chronic phase of chronic myeloid leukemia (CML) subjects with the 
significant fold value of 8500 in both phases of CML compared to healthy group. No 
studies have reported the role of UTRN in CML disease.  
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PTPRJ_3 Is the isoform 1 precursor of receptor-type tyrosine-protein phosphatase, 
receptor type J, PTPRJ. This protein is expressed in colon carcinoma. In a study, the 
gene was found to be pathogenic in two of seven cases. In the present study, this 
variant of PTPRJ was significantly downregulated in both complete remission and 
chronic phases but it has the optimum level of significant value of 10
-6
 with the 
highest fold of 4100 in healthy group only.  The gene is known for its role in breast 
cancer, lung cancer and colorectal cancer, where the loss of heterozygosity of PTPRJ 
is a common occurrence. Nevertheless, both the functions and mechanism of the gene 
in cancers are not well understood. In their study, Zhang, Tu, Li, Ye, and Cui (2017) 
were able to demonstrate that the ectopic expression of the gene leads to the inhibition 
of cell growth and mitigates the invasion of the colorectal cancer. When a xenograft 
tumor model was used, PTPRJ inhibited tumorigenecity of HCT116 cell line. 
Overexpression of PTPRJ minimizes the growth-promoting and AKT signaling 
activation of miR-155 (X. F. Zhang, Tu, Li, Ye, & Cui, 2017) This property of the 
gene is an indicator of its role as tumor suppressor and accordingly, might be used as 
a potential therapeutic target to decrease the proliferation and migration of the 
cancerous cells (Jayavelu et al., 2016) 
SCAPER_6. Is a transcript variant X6 and is a predicted gene encoding S-phase 
cyclin A associated protein in the ER (SCAPER). This gene encodes for a protein 
which interact with a complex of cyclin A and cyclin-dependent kinase2 (CDK2) via 
cyclin binding motif known as RX This interaction occurs at different stages of the 
cell cycle, particularly the transition process of the cell cycle from S to G2/M phases. 
Is found in the endoplasmic reticulum (ER) and in nucleus but is also considered as 
perinuclear protein. The unique function of the SCAPER protein is to maintain cyclin 
A homeostasis in the cytoplasm. Ectopic expression of the SCAPER protein leads to a 
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reduction of cyclin A level in the nucleus and retardation in cell cycle progress 
(Tsang, Wang, Chen, Sanchez, & Dynlacht, 2007) Northern blot analysis shows that 
SCAPER gene is ubiquitously expressed in all human tissues with a constant level, 
suggesting that SCAPER gene is housekeeping gene. Aberrations in SCAPER gene 
associated with 12 pathogenic variances and can be implicated in multiple pathogenic 
conditions such as intellectual disability, Rod-cone dystrophy, Attention deficit 
hyperactivity disorder and retinitis pigmentosa ("Gene ID: 49855 SCAPER S-phase 
cyclin A associated protein in the ER [ Homo sapiens (human) ]," 2018) Furthermore, 
the permanent binding of SCAPER protein to cyclin A/CDK2 complex is concordant 
with an increase of cyclin A level in the cytoplasm, which promotes cells growth and 
transformation. Therefore, SCAPER bounded cyclin A might be contributes in 
carcinogenesis Thus, SCAPER protein could be considered as a potential therapeutic 
target of cancer (Tsang et al., 2007) Flossbach L. et al., 2013 showed that the gain or 
loss mutation of SCAPER gene associated with small cell marginal zone B-cell 
lymphoma (SC MZBL) However, high level of SCAPER gene in this type of B-cell 
lymphoma can decrease the transition process between the cell cycle phases, thus 
reduce the cell growth and transformation to large cell lymphoma (Flossbach et al., 
2013) In the present study, this variant of SCAPER was significantly upregulated in 
both complete remission and chronic phases and it shows an increased fold of 1100 in 
both chronic pahse and complete remission . SCAPER protein regulates the cell cycle 
progression through interacting with cyclin A/kinases complex. It is found that this 
gene has a dual function in chronic myeloid leukemia, such as in promoting the 
growth of leukemic cells. However its upregulated expression will slow down the 
proliferation of leukemic cells and tend to transform to complete remission phase of 
CML disease.  
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Table 7.The promising genes (transcripts) in different CML groups of the study 
subjects. 
 
Transcript 
Name 
CP CR CNT 
Significant fold 
change values  
MAZ_ 4   √ 200 
RIT1_3   √ 600 
PTPRJ_3   √ 4100 
BUB1_4 √   6500 
U2SURP_3 √   2100 
SEPT9_2 √   2100 
SENP5_6 √   264 
TBC1D4_8            √  2200 
HNRNPA3_4            √  2200 
UTRN_7 √           √  8500 
LUZP1_5 √           √  1100 
SCAPER_6 √           √  1100 
PXK_20 √           √  CP: 1100,  CR: 800 
PLXNB2_8            √ √ CR: 1100, CNT:130 
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CHAPTER 5: CONCLUSION 
Due to high rate of the treatment failure among CML patients in Qatar, profiling of 
genes (transcripts) expression was studied. In our cohort of CML patients, differential 
transcripts expression was identified within the same group of CP phase which could 
explain that patients respond to the treatment diversely. These significantly expressed 
transcripts are SEPT9, U2SURP, BUB1, and SENP5 which could be used as 
prognostic biomarkers of the chronic phase of CML. 
This study also provides sets of genes as promising findings that have the potential to 
be used to stratify CML patients into complete remission and chronic phase groups 
and to monitor those who are at risk of relapse these transcripts are: LUZP1, SCAPER, 
UTRN, and PXK. Transcripts that are significantly upregulted in complete remission 
subjects only including TBC1D4, and HNRNPA3 these two transcripts have the 
potential use for following‐up and to determine the treatment dose. Furthermore, 
some of these differentially expressed genes might be used as potential therapeutic 
targets. PLAXNB2 and CYTH4 transcripts which are significantly upregulated in both 
complete remission subjects and in healthy individuals could be used for monitoring 
the CML patients who are under treatment. PTPRJ_3 is another promising transcript 
as tumor suppressor which significantly upregulated in healthy individuals only. 
Limitations and Strengths 
Given the small population of Qatar, close to 2 milion, and low incidence rate of 
CML, we were successful to recruit 13 patients from two stages of CML disease, 
Chronic Phase and Complete remission. However, we wished to have an equal 
number of subjects in each group. One of the limitations of this study was the small 
sample size with no patients in blast crisis (BC) phase. Another limitation is the scope 
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of the analysis that only focused on the transcript expression. However, not to be 
included in this thesis, a number of analysis is under way, where the gene expression 
and fusion proteins will be mapped and compared to the results presented in this 
study.  The main strength of this project is the number of the patients recruited in the 
chronic phase. 
Recommendations 
For the future study, a longitudinal follow up of few patients may help to validate the 
current observation. It would also help to include those patients that are undergoing 
treatments. Although, very hard, including their first of kin, this might also help to 
distinguish inter individual variation from that of disease related. According to 
apparent results we gained from our study of the differential genes expression sets 
recognized in three groups of CML using RNA-sequencing, this will emphasize the 
using of this advanced method in diagnostic fields due to its high sensitivity since this 
technology considered as the highly dynamic method which has the capability to 
detect the novel genes and study them from all aspects. Also we are looking forward 
to recruit patients in blast crisis (BC) phase to study their transcript profile and to 
increase the number of the study subjects in order to translate the current findings to 
the clinical field. However, further accurate classification of CML is also 
recommended. 
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